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ABSTRACT 
 
 
Evaluation of Bone Biochemical Markers and Inflammatory Markers in Yearlings Fed  
 
Varying Ratios of Omega-6 and Omega-3 Polyunsaturated Fatty Acids.  
 
(December 2006) 
 
Trinette Noel Ross, B.S., Montana State University 
 
Co-Chairs of Advisory Committee:  Dr. Gary Potter 
             Dr. Pete Gibbs  
 
 
 
 Diets formulated to contain varying ratios of omega 6 to omega 3 fatty acids were 
fed to exercising yearlings to evaluate bone activity and inflammatory response.  Nine 
Quarter Horse yearlings were arranged within a triplicated 3 X 3 Latin Square 
experimental design and fed one of three diets.  Exercise protocol was designed to 
stimulate sub-clinical inflammation and normal bone response. 
 Body weight and physical growth measurements were not different between 
groups (P > 0.05), and feed intake was similar between groups (P > 0.05). 
 Horses consuming soybean oil (SBO) diet had lower fatty acid profiles (% by 
weight) of C16:0 and C16:1 (P < 0.05) when compared to horses consuming either corn 
oil (CO) or menhaden/corn oil (MCO) diets.  Though numerically different, percentage 
changes in C16:0 and C16:1 were not different between diets (P < 0.05).  Horses 
consuming MCO had significantly higher measurements of C20:4, C20:5 and C22:6 over 
the 28 day period when compared to horses consuming SBO or CO.  Percent change in 
mean concentrations of C20:5 were significantly different between the MCO group and 
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the SBO group (P < 0.05) with no observed difference between MCO and CO treatment 
groups. 
 Overall mean carboxyterminal telopeptide of type I collagen (ICTP) 
concentrations did not differ between diets (P > 0.05) nor was there a significant change 
from baseline values when compared to day 28 of the period. 
 Mean Osteocalcin (OC) concentrations did not differ between treatments (P > 
0.05). Numerically, OC levels were lower after 14 days, with subsequent increases 
occurring from day 14 to day 28; however, there was no significant day effect (P > 0.05). 
 Mean measurements of PGE2 and fibrinogen, the two inflammation markers 
evaluated, did not differ among groups (P > 0.05). However, when fibrinogen data were 
normalized, horses consuming SBO had a significantly lower change in baseline values 
of fibrinogen compared to horses fed CO or MCO diets (P< 0.05).   
In general, horses fed SBO exhibited reduced levels of the inflammatory marker 
fibrinogen (P< 0.05). No other variable evaluated was influenced by the supplementation 
of varying ratios of polyunsaturated fatty acids into the equine diet.    
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CHAPTER I 
 
INTRODUCTION 
 
 
 The evaluation of omega 6 and omega 3 polyunsaturated fatty acids (PUFA) and 
their application in the mammalian diet has been the subject of nutritional inquires for 
years. Research has hypothesized that elevated omega 3 fatty acids in the diet may 
provide a protective effect to inflammatory responses in humans (Kettler, 2001) as well 
as reducing the incidence of bone loss in geriatric subjects (Terano, 2001).  
The evaluation of polyunsaturated fatty acids in the equine diet is limited; 
however, its popularity has increased in recent years with the development of more 
palatable fat sources. In the limited information available on essential fatty acid in the 
equine diet; it has been established that elevating omega 3 PUFA content of the diet 
results in a dose-dependent incorporation of those fatty acids into equine cellular 
membranes and bloodstream (King et al., 2005). Most research evaluating omega 3 
PUFA mediation of inflammatory processes in horses have relied on in vitro 
methodology.  Very few queries have used in vivo procedures to assess PUFA response 
to biological processes in the horse.  What information that is available appears to be 
promising.  Wilson et al. (2003) determined that exercising horses fed soybean oil 
expressed lower fibrinogen concentrations compared to the fibrinogen concentrations of 
exercising horses fed corn oil.  
Supplementation of omega 3 fatty acids have been confirmed to significantly 
influence constituents of rat bone; increasing formation markers such as bone alkaline 
___________ 
This thesis follows the style and format of the Journal of Animal Science. 
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phosphatase (Watkins et al. 2000), decreasing bone PGE2 concentrations (Green et al., 
2004) and increasing calcium concentrations in the bone (Claassen et al., 1995).  
 At present, there has been minimal research investigating the supplementation of 
omega-6 and omega-3 PUFAs in the equine diet and its potential influence on 
inflammation. To the best of our knowledge there has been no research probing the 
effects of essential fatty acids on the equine skeletal system.  Therefore, such an 
investigation is warranted and necessary to better understand the role these essential fatty 
acids play in biological pathways of the horse. The objectives of the present study were:   
1) Investigate the effect of dietary omega-3 PUFAs from two sources on bone  
biochemical markers in young, rapidly growing horses 
2) Evaluate fat supplemented diets and compare any influence on sub-clinical 
inflammation in young, exercising horses 
3) Evaluate different dietary ratios of omega-6: omega-3 PUFAs in the equine diet 
and their composition in the blood 
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CHAPTER II 
 
REVIEW OF LITERATURE 
 
 
Bone Development In The Growing Horse 
Proper bone development is essential in the young performance horse to ensure 
the skeletal structure of the animal will remain sound throughout training and 
competition. The physical demands of training submit these animals to excessive 
biomechanical strain; an undesirable condition impressed on an immature bone structure.  
Studies evaluating juvenile Thoroughbreds in training listed structural unsoundness as the 
primary causes of training failure (Bailey et al. 1999, Boston and Nunamaker 2000, 
Hernandez and Hawkins, 2001, Wilsher et al., 2006). 
In a physiologically normal, mature horse, bone activity remains constant 
throughout its lifespan. In the growing horse, bone formation exceeds resorption, 
resulting in skeletal hypertrophy. Bone modeling involves the activation of osteoblasts, 
mononuclear bone cells which function to deposit mineral; adding shape, width and 
length to the bone matrix.  During this phase, approximately 100% of the bone surface is 
active to achieve such a dynamic change (Watkins et al., 2001a). This significant increase 
in bone mass only occurs in the young horse, while bone remodeling is always occurring 
to some extent. Bone remodeling is the coupled process of resorption and formation. 
Under normal circumstances, there is no net loss or gain of bone. There are six phases of 
remodeling:  quiescence, activation, resorption, reversal, formation and a return to 
quiescence.  During both quiescence phases, osteoblasts are dormant and are laying flat 
along the bone surface.   
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Osteoclasts are multinucleated cells whose function is to break down the bone 
matrix resulting in the release of such minerals as calcium and phosphorous into the 
blood stream. Initiation of bone resorption occurs when mechanical loading, insult to the 
limb or abnormal metabolic activity stimulates a hormonal response which activates pre-
osteoclastic cells.  
During the resorption phase, osteoclasts are responsible for the removal of bone, 
leaving indentations within the matrix known as Howship lacunae. The amount of bone 
removed is dependent upon the volume and activity level of the osteoclasts (Sampson, 
2005), with an increase in activity leading to an increase in bone resorption.  Osteoclasts 
presence begins to decline with the subsequent appearance of new osteoblasts into the 
Howship lacunae during the reversal phase. Formation involves the synthesis of bone 
matrix and mineralization orchestrated by the presence of the new osteoblasts. Again, the 
degree of formation is dependent upon the amount of mononuclear cells and their 
contributing activity (Sampson, 2005) assuming all processes are undergoing normal 
metabolic functions.  Mineralization of mature bone is approximately 76% in equines at 
one year of age (Lawrence, 2003) with approximately 50% of the primary equine 
skeleton being replaced, through remodeling, by three years of age (Marlin and 
Nankervis, 2002).  In short; equine bone is extremely dynamic and active, with a short 
window of opportunity in which to maximize bone density and strength.   
It has been well documented that weight-bearing activity is necessary to stimulate 
bone activity as well as maintain bone integrity and health. The conception that bone will 
adapt to environmental stress by altering its shape and composition is known as Wolff’s 
law; early work by Woo and colleagues (1981) validate the concept in swine.  Some form 
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of mechanical loading of the bone is required in order for bone density to increase in 
volume, thus providing a more stable foundation in which to accommodate impact. This 
concept has been thoroughly investigated and validated by a number of equine 
researchers (Nielsen et al., 2002, Hiney et al., 2000, Hoekstra, et al., 1999, Bell, et al., 
2001).  The degree and duration of physical activity necessary to achieve optimal bone 
growth and density has also been investigated and substantiated (Nielsen et al., 1997, 
Buckingham and Jeffcott, 1991, Jeffcott et al., 1987) with certain intensities being 
specific for the type of activity the horse is engaged. Hiney (2004) presented reviewed 
literature on bone development in horses, indicated that the age of the animal is crucial 
for bone development; as the juvenile animal is better suited for bone adaptation to 
exercise than the mature animal.  For the purpose of the present study, the exercise 
protocol was designed to mimic the normal pasture activity of rapidly growing yearlings. 
Omega 3 and Omega 6 Polyunsaturated Fatty Acids   
 Research in human nutrition has indicated how the supplementation of particular 
fats in the diet can have beneficial effects on inflammation and bone metabolism.  The 
particular fats mentioned are the class of omega 3 fatty acids, found in the largest 
quantities in marine fish oil. Typical horse diets consist of the addition of plant-based oils 
such as corn or safflower. However these tend to be high in the omega 6 fatty acids, 
mainly Arachidonic acid (AA). This fatty acid is the parent of inflammatory responders 
known as prostaglandins, leukotrienes and thromboxanes. These compounds are 
necessary in the inflammatory response; however, if large concentrations are circulating 
in the system, the inflammatory mechanism can be exacerbated. 
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During lipid metabolism, the most common long chain omega-6 fatty acid is 
arachidonic acid (AA) while the most common long chain omega-3 fatty acid is 
eicosapentaenoic acid (EPA). Arachidonic acid derivatives include PGE2, thromboxane 
A2 (TXA2) and leukotriene B4, all part of a family of very effective signaling molecules 
responsible for inflammation and platelet aggregation. Eicosapentaenoic acid derivatives, 
prostaglandin H3 (PGH3) and thromboxane A3 (TXA3) are regarded as less potent 
substrates when compared to AA derivatives. Lee et al., (1991) commented that EPA 
competes with AA for metabolism by the cyclooxygenase and lipoxygenase pathways; 
therefore when available in adequate quantities, EPA can depress the production of the 
pro-inflammatory metabolites of AA, through its own production of the less 
inflammatory eicosanoids.  Excess AA can lead to the increase in the formation of 
Prostaglandin E2, its ω-6 derived eicosanoid. In adequate levels, PGE2 is instrumental in 
many biological processes; however, excess amounts can be detrimental, promoting 
unnecessary bone resorption (Watkins et al., 2000) and exacerbating inflammatory 
responses (Calder, 2002). 
One of the premier sources of eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA) is marine fish oil, also known as menhaden oil. Several studies have used 
menhaden oil as a supplement; however there is often difficulty when trying to 
incorporate it into equine diets due to poor palatability.   
Eicosapentaenoic acid, though found in the largest quantities in marine fish oil, 
originates from alpha linolenic acid (ALA) which is converted from linolenic acid (LA) 
in plants. Plant oils such as linseed, soybean and flaxseed oils are all good sources of 
ALA, therefore, when consumed; the animal should be able to synthesis EPA and DHA 
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from these plant oils.   In the use of the plant source of omega-3 fatty acids, EPA has 
been documented to inhibit the synthesis of AA from LA, decreasing inflammatory and 
procoagulant responses (Henry et al., 1990).  One study involving western performance 
horses concluded that feeding horses a soybean oil diet did not increase fibrinogen 
concentration (an indicator of inflammation) when compared to horses fed a non-fat 
supplemented diet. Additionally, those horses fed the omega-3 diet appeared to recover 
quicker from inflammation when rested compared to horses fed an elevated omega 6 diet. 
(Wilson et al., 2003). Another study comparing corn oil to menhaden oil concluded that 
mean PGE2 production was greater in horses fed a corn oil diet when compared to the 
horses fed a fish oil diet over a 12 week period (Hall et al., 2004). 
 Diets containing increased levels of omega 3 PUFA have been shown to regulate 
inflammatory cytokine production in both arthritic human subjects (Kremer et al., 1987) 
and healthy men and women (Endres et al., 1989, Meydani et al., 1991) after at least 4 
weeks of diet change. Other studies using feline and canine subjects concluded that diets 
enriched with omega-3 PUFA appear to suppress cell-mediated immune response 
(Wander et al., 1997) and alteration in platelet aggregation (Saker et al., 1998), 
respectively.  
Dietary fat sources that exert potent biological roles on the skeletal tissues belong 
to the omega 6 and omega-3 families of essential fatty acids; with their derivatives of 
prostaglandins, cytokines and insulin-like growth factors influencing skeletal biology 
(Watkins et al. 2001a).  Feeding varying ratios of omega-6: omega-3 fatty acids have 
been shown to alter PGE2 production in bone, leading either an increase in bone 
formation or a decrease in bone degradation (Korotkova et al. 2004; Requirand et al. 
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2000; Watkins et al. 2000). It appears that these essential fatty acids may also influence 
calcium absorption in animal subjects (Claassen et al., 1995, Kruger et al., 1997, Kelly et 
al., 2003) as well as blood calcium levels in horses (Hall et al., 2004).   
Bone Biochemical Markers   
 A non-invasive method in evaluating bone activity is the use of bone biochemical 
markers. This practice has been utilized for years by human researchers and has been 
readily accepted into equine research in the past decade. The use of systemic markers 
identifies overall bone health; however it lacks specificity in identifying abnormalities in 
certain bones.  Biochemical markers are ideal for ‘real-time’ assessment of bone activity 
and are useful for short-term evaluation, where as radiography provides a more 
unambiguous appraisal of bone health, providing a more specific identification of 
atypical bone.  
 Osteocalcin (OC) is a vitamin-K dependent, calcium binding protein (Price et al., 
1976) produced by active osteoblasts during formation. Intacted remnants of this non-
collagenous protein are excreted into circulation, where measurable increases in the blood 
indicate bone formation. Osteocalcin however does not reflect true osteoblastic activity, 
as the protein is incorporated into the new matrix as well as released during degradation 
(Kleerekoper, 1996). Therefore, OC is a better indicator of total bone activity rather than 
a gauge of bone formation.  The use of OC as a bone biochemical marker has been used 
as a measure of bone turnover in both juvenile (Lang et al., 2002, Fenton et al., 1999) and 
mature horses (Price et al., 1995, Black et al., 1999). There appears to be a diurnal 
variation in serum OC levels with the highest concentrations being seen in the early 
morning hours (0200h-0900h) with peak levels occurring at approximately 0500h   
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(LePage et al., 1991, Black et al., 1999). Consequently, care must be taken relative to the 
time of day samples are collected.  
 During bone turnover, osteoclasts work to breakdown mineral as well as the 
collagen structure that makes up 90% of the bone matrix. The carboxy-terminal 
telopeptide of type I collagen (ICTP) is released into the blood during degradation with 
its concentration being subsequently measured in serum samples. An assay developed in 
1993 detects ICTP as a marker of bone degradation (Risteli et al., 1993) and such 
methods have been used and validated in a number of investigations involving horses 
(Hiney et al., 2000, Michael et al., 2001, LePage et al., 1998, Price et al., 1995).  
Acute Phase Response    
Modifications to cellular metabolism and function due to excessive exercise, heat 
stress, tissue trauma or exposure to viruses contributes to a process known as “acute 
phase response”. This is an early and immediate response within the inflammation 
process.  Physical, environmental and internal stresses stimulate the reaction of 
monocytes and macrophages by initiating local and systemic changes. Early in the acute 
phase response, the events remain localized at the site of injury. This results in the 
identification of any loss of vascular integrity demarcate damaged tissues and recruit cells 
for the subsequent reparative phase, which involves a systemic response (Blok et al., 
1996). Initial events involve macrophages or monocytes that stimulate the release of 
certain cytokines, in particular, interleukin-1 (IL-1) and tumor necrosis factor (TNF). IL-
1 and TNF trigger additional cells to release pro-inflammatory prostaglandins, such as 
PGE2, that works to modulate immune functions during inflammation. These particular 
mediators create alterations such as induction of fever, vasodilatation resulting in tissue 
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edema, and changes in the metabolism and gene expression within the liver.  The liver is 
the target organ of systemic inflammatory regulation and is responsible for identifying 
the type of metabolite needed to support the animal during critical stages of stress 
(Baumann and Gauldie 1994).  Hepatic contribution to inflammation involves decreasing 
the production of conventional plasma proteins, such as albumin and transferrin, while 
increasing the production of acute phase proteins such as serum amyloid A, 
ceruloplasmin and fibrinogen.   
 The acute phase response has been measured in horses by use of inflammation 
models such as the tissue-cage model (Higgins and Lee, 1984a), polyester sponge model 
(Higgins et al., 1987) and subcutaneously placed tissue chambers (Guthrie et al., 1996).  
These studies all used a carrageenan-induced method of inflammation with observed 
increases in either cytokine, prostaglandin or acute phase protein concentrations.  
Intramuscular injections of Freund’s adjuvant into the neck of horses were successful in 
initiating an inflammatory response (Mills, et al., 1997; Auer et al., 1989). These are all 
excellent methods in which to evaluate the inflammatory response, however, there is 
limited research involving exercise-induced inflammation in horses. As a result, there is a 
great need to better understand how horses respond to training and to evaluate possible 
suppressors of inflammation generated through exercise. 
Fibrinogen      
One type of acute phase response protein is fibrinogen. Synthesized by the liver, 
fibrinogen’s primary occupation is system hemostasis. Through the activity of thrombin, 
fibrinogen is cleaved into fibrin, an insoluble fibrous protein that required in the 
coagulation cascade and subsequent clotting mechanisms that occur post-injury.  Horses, 
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compared to other species, are efficient in producing fibrinogen as a result of trauma, 
therefore, determining fibrinogen concentrations and measuring its change is a reliable 
indicator of inflammation (Andrews et al., 1994).  Evaluation of fibrinogen levels is 
relatively simple, due in part to a method developed in 1971 (Millar et al.) and 
subsequently validated in horses by Campbell and associates in 1981. The procedure has 
been adopted for use in clinical settings due to its simplicity and has been an acceptable 
assay in equine research as well.  
 Normal levels of fibrinogen in horses have been identified as between  
200-400 mg/dl, with values greater than 400 mg/dl regarded as a marker of inflammation.  
Increases in mean plasma fibrinogen above baseline values indicate the presence of acute 
phase response in horses (Mills et al., 1997, Schalm, 1979) with the degree of increase 
appearing to be related to the severity of injury (Allen and Kold, 1988).  Observations of 
plasma fibrinogen conclude that fibrinogen concentrations increase immediately once 
acute phase response is initiated with peak levels occurring around d 6 and remaining 
elevated for several days (Allen and Kold, 1988, Mills et al., 1997, Wilson, et al., 2003).  
It should be noted that fibrinogen concentrations are also an indicator of inflammatory 
resolution, with concentrations decreasing immediately after peak values and ultimately 
returning to baseline values within a reasonable timeframe.  
Prostaglandin E2   
Prostaglandins are a part of a family of potent eicosanoid lipid mediators derived 
from the cellular membrane bound n-6 fatty acid arachidonic acid (AA). AA is stimulated 
by phospholipases to be released from the cell and by interaction of cycloxygenase 
enzymes; yield eicosanoids. The exemplary characteristics of “true” eicosanoids are their 
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sterochemical precision in formation and recognition of their target tissues, effectiveness 
in the nanomolecular range in vitro and their authentic involvement in biological 
activities (Funk, 2001).  The predominate prostaglandin found in most mammalian cells 
is prostaglandin E2 (PGE2), an important arbitrator of several biological processes, 
particularly immune response. PGE2 is produced by several classifications of mammalian 
cells, such as macrophages, mast cells and fibroblasts, indicating that evaluation of their 
concentrations would provide a good interpretation of their involvement in bone activity 
and immune response.   
 Quantifying measurement of PGE2 concentrations in horses is limited, with a 
majority of available information based on in vitro studies with either equine 
macrophages (Hall et al., 2004), equine articular chondrocytes (Munstaman et al., 2005) 
or equine synovial explants (Bertone et al., 2001).  However, all fore mentioned inquiries 
were able to elevated PGE2 concentrations above baseline when an inflammatory 
stimulator was introduced, verifying the presence of PGE2 during the inflammatory 
response in the horse.  PGE2 concentrations varied depending on source of samples; 
normal synovial fluid PGE2 concentrations were established at approximately 9.5 pg/ml, 
with levels exceeding 22 pg/ml indicating the presence of joint disease (Bertone et al., 
2001).  In vivo studies evaluating PGE2 concentrations in tissue fluid established normal 
mean values at 2439 +/- 937 pg/ml (Guthrie et al., 1996) and 2900+/-300  pg/ml (Higgins 
and Lee, 1984a). When stimulated, PGE2 concentrations peaked on average at 27,572 +/-
9607 pg/ml (Guthrie et al., 1996) and 197,000+/- 6490 pg/ml (Higgins and Lee, 1984a) 
respectively.   
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 There is little available information on the quantity of PGE2 in equine blood and 
alteration in levels occurring during the acute phase response. Previous measurements 
taken after exercising horses revealed no detectable concentrations of PGE2 (Mitten et 
al.,1995), however authors concluded that levels were most likely below the limits of 
sensitivity (50 pg/ml) for the assay they were using. Investigation of eicosanoid levels in 
normal horses specified mean digital vein PGE2 concentrations to be 187.18 pg/ml under 
resting conditions (Owens, et al., 1995). Further queries of plasma PGE2 levels in 
exercising horses are necessary to better understand its involvement during exercise-
induced inflammation.  
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CHAPTER III 
 
MATERIALS AND METHODS 
 
 
Animals and Background Period  
Nine yearling Quarter Horses were blocked by gender and age and randomly 
assigned to a triplicated 3X3 Latin square design of diet treatments. Horses averaged 352 
kg in body weight and were approximately 14 months of age at the start of the 
experiment. Prior to beginning the pre-trial period all horses were evaluated for health 
status. The horses were placed on a routine deworming, inoculation and feet trimming 
schedule. Horses were maintained at the Texas A&M University Horse Center following 
management protocol as stated in the Animal Use Protocol approved by the Institutional 
Agricultural Animal Care and Use Committee.   
 A 14 day pre-trial conditioning period was conducted prior to the beginning of the 
experiment to achieve a comparable level of fitness and to achieve a baseline level of 
physiological effects of exercise among all horses.  Yearlings were accustomed to a 
mechanical freestyle equine exerciser prior to the beginning of the experimental periods. 
The equine exerciser (Summertree Co., Inc.) is designed with an interior track consisting 
of six individual paneled sections, allowing horses to be exercised freely without being 
tied to the apparatus. Exercise on d 1 consisted of a total of 10 minutes of walking and 10 
minutes of trotting. Exercise adaptation on d 2 involved a total of 7 minutes of walking 
and 17 minutes of trotting.  By the third day in the freestyle exerciser, horses were 
walking for a total of 10 minutes, trotting for 13 minutes and loping for 8 minutes. By d 4 
horses were walking for 7 minutes, trotting for 18 minutes and loping for 6 minutes. On d 
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5 of background exercise, yearlings were walking for a total of 8 minutes, trotting for a 
total of 16 minutes and loping for a total time of 8 minutes.  Exercise on d 6-8 had the 
horses walking for an average of 6 minutes, trotting for an average of 13.5 minutes and 
loping for approximately 10 minutes.  All times for the various gaits indicated were 
equally divided throughout each exercise session, with a change of direction occurring 
half way through the session to allow for equal loading of each front limb. 
Experimental Diet 
 Each period involved 28-d of diet adaptation and exercise protocol. Diets 
consisted of a formulated concentrate containing either 8% corn oil (CO), 8% 
mechanically extracted soybean oil (SBO), or a 3:1 ratio corn: menhaden oil1 mix with 
volume equaling 8% of the diet (MCO) (Table 1). Oils were measured out for each 
individual horse and kept refrigerated (4° C) until they were topdressed on concentrates 
during feedings. Yearlings were fed a coastal Bermuda grass hay to meet fiber and 
additional nutrient requirements. Diets were formulated to be isocaloric and based on the 
NRC requirements (1989) for yearlings undergoing rapid growth and according to 
recommendations by Nielsen et al. (1998) and Michael et al. (2001). Concentrate was 
formulated by authors, though mixed and bagged by Producers Cooperative, Bryan, 
Texas. Table 2 shows the nutrient composition of the three diets. The total diet was 
comprised of 52% extruded concentrate, 8% assigned oil, and 40% coastal Bermuda 
grass hay. 
 
________________ 
1Omega Equis, Omega Protein Inc. Houston, TX . 
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Table 1. Composition of total diet (%; as fed) 
Diet Composition 
      % 
Forage 40 
Oats 15.73 
Corn 19.24 
Soybean Meal 13 
 Salt 0.26 
Molasses 2.08 
Dical 0.52 
Vit/Min premix 0.26 
Limestone 0.91 
Oil 8 
Total 100 
  
 
Table 2. Calculated composition of diets (as fed) 
Component   Corn Oil   Menhaden/Corn Oil Soybean Oil   
    Supplemented Diet Supplemented Diet Supplemented Diet 
Digestible  
Energy         
   Mcal/kg  3.15  3.16  3.15   
          
Crude Protein %  13.44  13.44  13.44   
g/Mcal  42.67  42.53  42.67   
          
Crude Fat  %  10.56  10.56  10.56   
g/Mcal  33.52  33.42  33.52   
          
Ca        %  0.70  0.70  0.70   
g/Mcal  2.22  2.22  2.22   
          
P           %  0.35  0.35  0.35   
g/Mcal  1.11  1.11  1.11   
          
Mg         %  0.16  0.16  0.16   
g/Mcal  0.51  0.51  0.51   
          
K            %  0.90  0.90  0.90   
g/Mcal   2.86   2.85   2.86   
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Horses were housed in groups of three in 9 X 9 meter dry lot pens with water 
offered ad libitum. Horses were individually fed their designated diets in two equal 
feedings per day at 0600h and 1800h. Initial ration amounts were based on approximately 
2% BW of each individual horse with rations adjusted as needed to maintain a body 
condition score between 5 to 6 (Henneke et al., 1983). 
Experimental Exercise Protocol   
On d 1- 5 of each week horses were subjected to a standardized exercise protocol 
consisting of 2 minutes of walking, 3 minutes of trotting, 30 seconds of walking, 4 
minutes of loping, 1 minute of walking, 3 minutes of loping, 1 minute of walking, 3 
minutes of loping, 2 minutes of walking, trotting for 2 minutes and finally a warm down 
of 3 minutes of walking.  Horses changed direction during each exercise session after 
either the first or second lope, preventing excessive loading to any one particular limb.  
Measurements and Data Collection  
On d 0, 28, 56 and 84 of the experiment physical measurements were taken to 
evaluate growth.  Body weight and body condition scores were taken as needed 
throughout the experiment with feed rations adjusted if needed to maintain body 
condition.  Physical measurements included body weight, wither height, hip height, 
forearm circumference, gaskin circumference and heart girth.  On each measurement day, 
sample spots on the forearm, gaskin, point of the shoulder and point of the hip were 
clipped and measurements were taken from selected points within the clipped area.  
Subsequent measurements were taken from designated sample spots to minimize error.  
Fasting blood samples were taken from all horses prior to morning feeding on d 0, 
3, 7, 10, 14, 17, 21, 24 and 28 of each period via veni-jugular puncture. All blood 
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collections occurred at approximately 0500h in accordance with findings by Black et al. 
(1999) indicating the diurnal variation in bone biochemical markers.   
 Blood serum samples were harvested into single 10 ml blood collection 
evacuated tubes without additives. Venous blood samples for plasma were collected into 
duplicate 10 ml blood collection evacuated tubes containing lithium heparin. Additional 
blood was collected into single 5 ml evacuated tubes containing EDTA. One vial of the 
heparinized blood from each horse was kept refrigerated (4°C) for immediate fibrinogen 
analysis.  All other blood collection tubes were spun at 3,200 rpm in a balanced 
centrifuge at 4°C for 30 minutes.  After separation, plasma or serum from each tube was 
pipetted into labeled 1.5ml microcentrifuge tubes, properly capped and stored upright in 
Styrofoam carriers at -20°C until needed for analysis.   
Concentrate samples, oil samples and forage samples were taken at random 
throughout experimental periods for future analysis of fatty acid content and nutritional 
composition.  
Laboratory Analyses    
Dry matter content of concentrate and forage samples were conducted.  Feed 
samples were ground using a Wiley mill accommodated with a 1 mm mesh screen.  
Approximately 2.0 g of ground concentrate and forage sample were measured in 
triplicate into aluminum pans and placed in a drying oven (68°C) for 72 hours.  Pans 
were removed and placed inside a dessicator for cooling and to prevent condensation.  
Dry sample weight was determined by subtracting sample weight prior to drying from the 
sample weight after drying.  Dry matter percentage was calculated using the following 
formula: 
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  Dry sample weight (g) 
                                       X 100 
  Wet sample weight (g) 
 
Samples were reanalyzed if standard error was greater than 5%.   
 Plasma fibrinogen concentration of blood samples were assayed within 24 hours 
of blood collection. Fibrinogen concentration was determined using micro-hematocrit 
heat precipitation methods of Millar et al. (1971) and Wilson et al. (2003).  Whole blood 
was harvested into blood collection tubes containing heparin. Two 75 mm heparinized 
micro-hematocrit capillary tubes (Fisher Scientific) were filled at least 50% with whole 
blood and sealed at one end using critoseal (Oxford Labware).  The tubes were 
centrifuged for 5 minutes. Tubes were immediately transferred upright into a water bath 
(56 +/-2°C) for 3 minutes, centrifuged for an additional 3 minutes.  Using a digital 
caliper, the length of the fibrinogen column and total length of fibrinogen-plasma column 
was measured.  Fibrinogen concentration (mg/dl) of each sample was determined using 
the following equation: 
   Fibrinogen column 
          X 10,000 
   Fibrinogen-plasma column 
  
 Plasma samples, oil samples, concentrate samples and forage samples were 
analyzed for total fatty acid profiles using a gas chromatograph.  Heparized plasma 
samples were thawed, with 3 ml of plasma pipetted into 55 ml glass centrifuge tubes. 400 
μl of oil samples; and 1 g of dried ground concentrate and forage samples were placed in 
their respective 55 ml glass centrifuge tubes.  15 ml of a 2:1 solution of CHCl3: CH3OH 
was added to tubes and mixture was vortexed for 30 sec.  The homogenate was pipetted 
out and filtered through a Whatman filter apparatus using a 2.4 cm GF/C filter into a 
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second labeled 55 ml glass centrifuge tube. The first tube and the filter funnel were rinsed 
three times with CHCl3: CH3OH solution and filtered into a second labeled 55 ml glass 
tube.  Enough CHCl3: CH3OH solution was then added to each filtered homogenate 
sample to make the volume approximately 30 ml after which 8 ml of 0.74% KCl was 
added. Tubes were vortexed for 1 minute. Sample tubes were capped with nitrogen and 
stored (-4ºC) overnight in cooler to allow homogenate to separate into two separate 
phases.  Once phase separation occurred, the upper phase was carefully removed using a 
filter flask vacuum apparatus. The lower phase was transferred to clean, labeled 20 ml 
glass tubes. The 55 ml glass tubes were rinsed three times with CHCl3: CH3OH solution 
and transferred into the 20 ml glass tubes that contained the lower phase.  Samples were 
then placed into a Meyer N-Evap analytical evaporator to allow for complete evaporation 
of CHCl3: CH3OH solution, leaving only the dried lipid content of the original plasma 
sample. After evaporation, 1 ml of 0.5 N KOH in MeOH was added to each sample; 
which was loosely capped, and transferred to a water bath (70°C) for 10 min.  1 ml of 
14% BF3 in MeOH is then added to each sample. Tubes were then flushed with nitrogen, 
loosely capped and placed back into the water bath (70°C) for 30 min. Tubes were 
removed and allowed to cool to room temperature. 2 ml of GC-grade hexane and 2 ml of 
saturated NaCl was added to the samples.  Tubes were vortexed again for 30 sec. Upper 
hexane layer was removed and transferred into labeled 20 ml glass tubes containing ~800 
mg Na2SO4.  An additional 2ml of hexane were added to saturated NaCl tubes and briefly 
vortexed. The upper hexane layer was then transferred into the Na2SO4 tubes, which now 
contained ~ 4ml of hexane, and briefly vortexed.  Upper hexane layer was transferred 
into labeled scintillation vials. 1 ml of hexane was added to Na2SO4 tubes, and briefly 
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vortexed. Remaining upper hexane layer was transferred into labeled scintillation vials. 
Scintillation vials were then transferred to N-Evap to allow hexane to evaporate 
completely. Lipids in scintillation vials were reconstituted with 0.5 ml of hexane and 
mixed carefully. Oil samples were processed identical to plasma and feedstuff samples, 
with the exception of being reconstituted with 1 ml of hexane. 100µl of sample solution 
was pipetted from scintillation vials into labeled 2 ml autosampler vials.  Autosampler 
vials were then loaded into a Varian Chrompack automated gas chromatograph for 
analysis.  Lipids in scintillation vials were reconstituted with .5 ml of hexane. Oil 
samples were reconstituted with 1 ml of hexane. 100µl of sample solution was pipetted 
from scintillation vials into labeled autosampler vials. Autosampler vials were then 
loaded into a Varian Chrompack automated gas chromatograph for analysis. 
 Serum was assayed for concentration of the bone formation marker Osteocalcin 
using an enzyme immunoassay kit (Quidel Corporation, San Diego, CA).  Osteocalcin 
concentration was measured from serum samples obtained on day 0, 14 and 28 of each 
study period.  Serum samples were diluted 10-fold with saline solution according to 
modifications validated by previous research (Lang et al., 2002). 
 Additional serum samples were analyzed for the concentration of the carboxy-
terminal telopeptide of type I collagen (ICTP). Samples obtained on day 0, 14, and 28 of 
each period were assayed using a radioactive immunoassay (DiaSorin Inc., Stillwater, 
MN).  
 Prostaglandin E2 (PGE2) was analyzed from plasma samples collected on day 0, 3, 
10, 17 and 24 of each period.  Sample collections days were different from bone 
biochemical markers due to the days that weekly exercise commenced on. Blood was 
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drawn at the end of each week to avoid the weekend layoff causing variability in the 
inflammation measurement. An enzyme-linked immunoassay (R&D systems, 
Minneapolis, MN) was used, with all plasma samples requiring a 5-fold dilution with a 
provided calibrator diluent prior to beginning the assay.       
All laboratory assays were run in duplicate unless otherwise noted and were 
reanalyzed if the standard error was greater than 5%. 
Statistical Analysis 
 Data was analyzed for treatment, day and treatment-day-interaction by 
analysis of variance for Latin square using Stata Software (Stata Corp. 2004. College 
Station, Texas).  Period interaction was originally evaluated in all analysis of variance 
tests; however, if period interaction was not observed, the variable was dropped to allow 
for a stronger statistical model. In order to evaluate change within periods, hematological 
data was normalized to day 0 of each period, unless otherwise indicated. When main 
differences were observed at P < 0.05 level, means were further separated using the 
Bonferroni means comparison test. 
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CHAPTER IV 
RESULTS 
 
Feed Analysis      
The fatty acid profile of the concentrate is shown in Table 3. The concentrate 
contained 3.68% crude fat, with the relative percentage by weight of individual fatty 
acids in the concentrate to be 15.71% for C16:0 (palmitic acid), 32.69% for C18:1n-9 
(oleic ccid), 39.15% for C18:2 (linoleic acid) and 1.79% for C18:3 (alpha linolenic Acid).  
There were scant readings of C20:5 (eicosapentenoic acid) and C22:6 (docosahexanoic 
acid); however they were less than 0.5%. The n6:n3 ratio of polyunsaturated fatty acids 
of the concentrate was 18.41. 
The fatty acid profile of the forage is shown in Table 4.  The Coastal 
Bermudagrass hay contained 1.63% crude fat with the relative percentage by weight   
fatty acids identified being 23.20% C16:0 (palmitic acid), 4.69% C18:1n-9 (oleic acid), 
14.81% C18:2n-6 (linoleic acid) and 20.38% C18:3 (alpha linolenic acid).  The forage 
contained small amounts of C20:5 (EPA) and C22:6 (DHA) at 0.39% and 0.84% 
respectively. The n6:n3 ratio of polyunsaturated fatty acids found in the forage was 0.77. 
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Table 3.  Fatty acid profile of concentrate 
Fatty Acid                       % by weight 
C14:0  0.13   
     
C16:0  15.71   
     
C16:1n-7  0.16   
     
C18:0  2.77   
     
C18:1n-9  32.69   
     
C18:2n-6  39.15   
     
C18:3n-3  1.79   
     
C20:4n-6  0.21   
     
C20:5n-3  0.27   
     
C22:6n-3  0.07   
     
n6:n3 ratio 18.41     
 
Table 4. Fatty acid profile of Bermudagrass hay 
Fatty Acid                     % by weight   
C14:0  1.02    
      
C16:0  23.19    
      
C16:1n-7  0.1327    
      
C18:0  3.43    
      
C18:1n-9  4.69    
      
C18:2n-6  14.81    
      
C18:3n-3  20.38    
      
C20:4n-6  2.02    
      
C20:5n-3  0.39    
      
C22:6n-3  0.83    
      
n6:n3 ratio 0.77       
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The chemical fatty acid analysis for corn oil is shown in Table 5.  Relative 
percentage by weight of fatty acids identified within corn oil were 11.86% C16:0 
(palmitic acid), 26.79% C18:1n-9 (oleic acid), 55.85% C18:2n-6 (linoleic acid) and 
0.98%C18:3 (alpha linolenic acid). There were non-detectable measurements of either 
C20:5n-3 (EPA) or C22:6n-6 (DHA) in the corn oil. The n6:n3 polyunsaturated fatty acid 
(PUFA) ratio of corn oil was 56.97. Corn oil was added to the concentrate in the amount 
of 8% of the diet. The n6:n3 polyunsaturated fatty acid ratio for the total CO diet was 
calculated to be 3.22:1. 
 
Table 5. Fatty acid profile of corn oil 
Fatty Acid                      % by weight 
C14:0  0.51   
     
C16:0  11.85   
     
C16:1n-7  0.44   
     
C18:0  2.24   
     
C18:1n-9  26.78   
     
C18:2n-6  55.85   
     
C18:3n-3  0.98   
     
C20:4n-6                                    ND*   
     
C20:5n-3                                    ND*   
     
C22:6n-3                                    ND*   
     
n6:n3 ratio 56.97     
*denotes non-detectable presence of interested fatty acid 
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Corn oil and Menhaden oil was mixed at a 3:1 ratio with volume equaling 8% of 
the total diet.  Chemical fatty acid profile of the mix is shown in Table 6. When analyzed, 
menhaden/corn oil mix had a fatty acid profile (% by weight) of 12.85% C16:0 (palmitic 
acid), 22.69% C18:1n-9 (oleic acid), 43.02% C18:2n-6 (linoleic acid) and 1.17% C18:3 
(linolenic acid).  Measurements of C20:5 (EPA) and C22:6 (DHA) were considerable at 
3.09% and 3.38%, respectively. Calculated PUFA n6:n3 ratio of the menhaden/corn oil 
5.64 :1.  The n6:n3 polyunsaturated fatty acid ratio for the total MCO diet was calculated 
to be 2.96:1. 
 
Table 6.  Fatty acid profile of menhaden/corn oil 3:1 Mix 
Fatty Acid                  % by weight     
C14:0  1.82     
       
C16:0  12.85     
       
C16:1n-7  2.49     
       
C18:0  2.43     
       
C18:1n-9  22.69     
       
C18:2n-6  43.02     
       
C18:3n-3  1.17     
       
C20:4n-6  0.16     
       
C20:5n-3  3.09     
       
C22:6n-3  3.38     
       
n6:n3 ratio 5.64         
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Results for mechanically-extruded soybean oil analyzed for fatty acid profile is 
shown in Table 7. Percentage by weight of specific fatty acids include 10.62% C16:0 
(palmitic acid), 20.78% C18:1n-9 (oleic acid), 55.09% C18:2 (linoleic acid) and 8.08% 
C18:3 (alpha linolenic acid).  There were no detectable measurements of either C20:5 
(EPA) or C22:6 (DHA) present in the mechanically-extruded soybean oil. 
Soybean oil alone contained a PUFA n6:n3 ratio of 6.81:1. The n6:n3 polyunsaturated 
fatty acid ratio for the total SBO diet was calculated at 2.96:1. 
 
Table 7.  Fatty acid profile of mechanically extruded soybean oil 
Fatty Acid                    % by weight 
C14:0  0.07   
     
C16:0  10.62   
     
C16:1n-7  0.07   
     
C18:0  4.17   
     
C18:1n-9  20.78   
     
C18:2n-6  55.09   
     
C18:3n-3  8.08   
     
C20:4n-6                                 ND*   
     
C20:5n-3                                 ND*   
     
C22:6n-3                                 ND*   
     
n6:n3 ratio 6.81     
*denotes non-detectable presence of interested fatty acid   
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Body Weight and Feed Intake 
 There were no significant difference in body weight among yearlings fed the 
different dietary treatments (P= 0.9876) (Table 8). Consumption of concentrate and hay 
were not statistically different between diets (P =0.6956) and (P =0.5940), respectively. 
Mean concentrate intake among all groups was 4.32 kg/d, with average forage intake 
among all horses approximately 2.85 kg/d. There were no palatability issues when oils 
were added to the concentrate. Any initial refusals of feed due to changing diets lasted no 
longer than one feeding.  
 
Table 8.  Body weight, concentrate intake, hay intake and total intake 
         Treatment    
Component   CO   MCO   SBO   
All 
Groups 
            
            
Weight (kg)  370.76  369.83  368.72  369.77
SEM   19.18  21.71  20.15  11.54
            
Concentrate Intake (kg) 4.31  4.26  4.407  4.32
SEM   0.16  0.10  0.14  0.07
            
Hay Intake (kg)  2.83  2.83  2.89  2.85
SEM   0.10  0.06  0.09  0.05
            
Total Intake (kg)  7.14  7.09  7.297  7.18
SEM     1.05   1.01   1.07   0.03
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Physical Measurements 
 Physical measurements taken on d 0 and d 28 of each period were analyzed for 
statistical differences among diets.  Measurements did not differ among treatments for 
wither height, hip height, body length, heart girth area, forearm circumference or gaskin 
circumference (P >0.05).  Mean values for physical measurements are listed in  
Table 9.   
 
Plasma Fatty Acid Profiles   
 Plasma samples acquired on d 0 and d 28 of each period were analyzed for 
identification of specific fatty acids. Percent by weight of plasma fatty acids identified on 
d 0 (baseline) are shown in Appendix 1. Mean basal fatty acid values (% by weight) were 
not different between groups (P > 0.05) and values were consistent with previous 
research evaluating equine plasma fatty acid profiles in yearling horses (Luther et al., 
1981). The mean value of plasma fatty acids identified on d 28 with percent change in 
plasma fatty acids from baseline (d 0) is shown in Table 10. 
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Table 9.  Influence of diet on parameters of growth 
  CO SEM MCO SEM SBO SEM 
Weight, kg       
  Initial 372.85 14.51 365.59 18.15 344.73 34.81 
  Final 398.56 12.06 378.29 28.11 404.91 8.18 
  Gain 32.96 8.92 33.56 7.25 32.05 7.63 
       
Wither Height, cm      
  Initial  133.56 1.38 136.74 1.84 139.06 3.72 
  Final 139.28 1.84 141.82 3.30 139.48 1.38 
  Gain 2.54 0 2.75 .56 5.92 2.77 
       
Hip Height, cm      
  Initial  142.45 1.28 143.72 .56 145.20 4.03 
  Final  146.05 .73 148.16 3.69 144.78 1.27 
  Gain 2.32 .76 2.96 .42 2.32 .56 
       
Body Length, cm      
  Initial  150.71 48.15 152.29 3.44 149.43 6.16 
  Final 152.08 5.30 155.25 4.86 156.11 1.16 
  Gain -.21 4.21 5.82 1.78 5.39 .84 
       
Heartgirth, cm       
  Initial  163.19 2.28 162.56 3.86 158.43 6.20 
  Final 170.71 2.32 165.1 6.00 170.07 1.37 
  Gain 8.14 1.70 6.66 1.45 6.87 1.07 
       
Forearm, cm       
  Initial  48.15 1.60 51.14 1.10 48.57 2.52 
  Final 51.54 1.22 48.57 3.53 49.42 1.10 
  Gain .39 .95 -3.97e-08 1.14 1.27 1.27 
       
Gaskin, cm       
  Initial  42.86 .66 43.49 .84 41.48 1.48 
  Final 44.87 1.48 42.55 1.14 43.18 .66 
  Gain 1.37 1.01 1.05 .38 .32 .36 
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Table 10. Mean plasma fatty acid profile on D 28 (% by weight) and percent change in 
fatty acid profile in response to dietary treatment 
 
Fatty Acid CO     MCO     SBO   
(% by weight) Mean  SEM   Mean SEM     Mean  SEM 
C14:0  0.11 0.05  0.03 0.02  0.02 0.01 
C14:0 (% Δ) 18.27 53.92  -69.80 18.98  -80.04 8.91 
          
C16:0   9.59a 0.56  8.83a 0.74  7.70b 0.68 
C16:0 ( % Δ) 0.63 10.02  -8.59 9.36  -21.28 6.65 
          
C16:1n-7  0.22a        0.02  0.20a 0.03  0.15b 0.02 
C16:1 n-7 (% Δ) -22.59a        9.01  -31.09a,b 9.01  -50.39b 8.24 
          
C18:0   16.90a,b        0.65  16.07a 0.81  18.58b 0.95 
C18:0 (% Δ) -4.96        4.44  -9.65 5.05  4.35 5.72 
          
C18:1   9.61 0.21  9.09 0.47  9.54 0.73 
C18:1 (% Δ) -5.84 3.59  -11.39 3.89  -3.21 11.93 
          
C18:2   55.98 1.34  54.56 0.45  57.08 0.61 
C18:2 (% Δ) 5.76 2.24  3.18 1.34  7.96 1.59 
          
C18:3   0.39 0.04  0.26 0.09  0.40 0.06 
C18:3 (% Δ) 4.37 40.82  -40.49 27.42  -9.15 36.75 
          
C20:4   1.18a 0.05  1.78b 0.07  1.38a 0.09 
C20:4 (% Δ) -37.89a 4.12  -7.02b 4.74  -28.14a,b 4.41 
          
C20:5   0.09a 0.09  1.36b 0.19  0.01a 0.01 
C20:5 (% Δ) 101.05a,b 114.08  355.36b 140.33  -21.62a 14.82 
          
C22:6   0.07a 0.03  1.64b 0.18  0.21a 0.05 
C22:6 (% Δ) -21.61a      16.91   678.98b 146.25   6.23a      28.01 
a,bRows not sharing common superscripts differ (P<0.05) 
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When horses were fed SBO, there was a significant decrease in plasma C16:0 
(palmitic acid) and plasma C16:1n-7 (palmoleic acid) percent by weight over 28 days 
when compared to horses consuming either MCO or CO diets (P<0.05).  Though 
numerical different, there were no difference in percentage change in C16:0 between 
diets (P > 0.05). Percent change in profiles of C16:1 were significantly lower in horses 
fed SBO diet when compared to horses consuming the CO diet (P < 0.021). 
Horses fed the SBO diet had a significantly higher plasma profile (% by weight) 
of C18:0 (steric acid) compared to horses consuming MCO diets (P < 0.05), however, 
there were no statistical difference between diets in percent change from baseline C18:0 
values (P > 0.05).   
 There were no differences in percent by weight measurements of myristic acid, 
oleic acid, linoleic acid or alpha linoleic acid among treatments.  Linoleic acid values (% 
by weight) increased in all horses over 28 days, while myristic acid, oleic acid and alpha 
linoleic acid values all declined regardless of dietary treatment.  Profiles (% by weight) of 
C20:4 (arachidonic acid) were significantly higher in MCO horses compared to horses 
being fed either SBO or CO diets (P = 0.0000). The menhaden oil provided an exogenous 
source of arachidonic acid, while both soybean oil and corn oil had non-detectable 
amount of arachidonic acid. The menhaden oil used in this study was 2.09% by weight 
arachidonic acid and when mixed with corn oil, MCO had an arachidonic cid % by 
weight of 0.16. However, the percentage change in arachidonic acid fatty acid profile 
from baseline fatty acid profile  (% by weight) were only significant between MCO 
horses and CO horses ( P < 0.0032), with C20:4 profile in SBO fed horses were similar  
to the other  two diets (P > 0.05).  
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  Percent change in C20:5 (EPA) and C22:6 (DHA) from basal profile 
measurements (% by weight) were significantly higher in horses fed the MCO diet 
compared to horses fed either CO or SBO (P < 0.0001). The MCO diet provided the sole 
source of EPA and DHA, with a significant level being identified in horses consuming 
the mixture over 28 days [1.36% (by weight) EPA and 1.64% (by weight) DHA].  MCO 
fed horses expressed a 3 fold increase in plasma C20:5 concentrations over 28 days, with 
changes in plasma profile being significantly different from horses supplemented with 
SBO (P < 0.0338).  Though numerically different, plasma profiles (% by weight) of 
C20:5 between corn oil fed horses and horses consuming the menhaden/corn oil mix did 
not differ (P > 0.05).  
 MCO fed horses had the highest levels of plasma C22:6 (DHA), compared to MO 
and SBO fed horses (P <0.0001), with percent change from baseline being significantly 
higher in MCO horses compared to horses supplemented with either corn oil or 
mechanically extruded soybean oil.  
 
Serum Carboxyterminal Telopeptide of Type I Collagen    
Serum samples taken on d 0, d 14 and d 28 of each period were analyzed for the  
bone degradation marker carboxyterminal telopeptide of type I collagen (ICTP) . Mean 
ICTP concentrations; separated by treatment and day, are shown in Appendix 2 and 
illustrated in Figure 1. 
Mean ICTP concentrations in exercising yearlings were not different among 
treatments (P = 0.4810) nor was there an effect of sampling day on circulating serum 
ICTP levels (P = 0.8903).  All horses regardless of diets had decreases in ICTP 
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concentrations from d 0 to d 14.  There appeared to be a numerical difference in ICTP 
levels between diets at d 28, however it was not statistically different (P = 0.5446). 
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Figure 1. Mean ICTP concentrations by diet over a 28 day period 
 
Due to large variation in ICTP levels among horses, data were normalized to d 0 
of each period to monitor change over 28 days. Normalized ICTP concentrations, 
separated by treatment and day, are shown in Appendix 3 and illustrated in Figure 2. 
There were no difference among treatments (P = 0.8887) or day (P = 0.8996) with 
normalized data. While not statistically significant, concentrations from horses 
consuming MCO diets appeared to drop sharply from d 0 to d 14 compared to the other 
diets, with a slight increase from d 14 to d 28.  ICTP concentrations remained constant 
through d 14 then exhibited a rapid decrease to d 28. Horses fed CO diets appeared to 
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have numerically higher ICTP concentrations at d 28 than at d 0 however when d 28 were 
isolated and analyzed, there were no significant difference between treatments  
(P = 0.5628).  
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Figure 2. Normalized mean ICTP concentrations by diet over a 28 day period 
 
Plasma Osteocalcin    
Bone activity in yearling horses was evaluated by analyzing Osteocalcin (OC) 
concentration in plasma samples collected on d 0, d 14 and d 28 of each period. Mean OC 
concentrations, separated by treatments and day are shown in Appendix 4. 
Based on mean unadjusted OC concentrations, there were no significant 
difference between treatments (P = 0.6865) or day within periods (P = 0.3119). 
Concentrations of OC among horses were not similar at d 0 (baseline) of the trial; 
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therefore values were adjusted to d 0 of each period and analyzed for change through d 
28. Normalized OC data, separated by day and treatment, are shown in Appendix 5. 
Normalized mean OC concentrations did not differ among diets (P = 0.4104), 
however there was a tendency for sampling day to effect OC measurements (P=0.1033).  
All Osteocalcin concentrations regardless of treatments numerically declined from d 0 to 
d 14, then increased between d 14 and d 28 (Figure 3). Horses fed MCO diets had the 
smallest numerical amount of change between d 0 and d 28, although there were no 
significance difference when compared to the other two dietary treatments (P>0.05) 
(Table 11). 
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Figure 3. Normalized mean osteocalcin concentrations over a 28 day period  
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Unfortunately, there was a significant period effect with normalized OC data  
(P = 0.0353), with Osteocalcin concentrations decreasing over time from period 1 
through period 3. (Table 12) Exercise was likely unsuccessful in stimulating a bone 
response during those time periods, resulting in a decrease in the bone marker.  
 
 
Table 11. Normalized mean osteocalcin concentration (ng/ml)  by diet and day   
Day        0  14  28 
CO (ng/ml)                                                 0   -9.22   -2.83 
SEM         0  6.07  4.63 
       
MCO (ng/ml)        0  -2.12  3.16 
SEM         0  4.4  6.28 
       
SBO (ng/ml) 0  -7.89  -0.98 
SEM   0   4.11   5.38 
 
 
Table 12. Normalized mean osteocalcin concentration (ng/ml) by period  
Period     1   2   3
OC (ng/ml)  1.89a  -1.57a,b  -6.94b
SEM           2.57   2.75   1.63
a,bRow means not sharing superscripts differ (P = 0.035) 
 
Plasma Prostaglandin E2   
 Prostaglandin E2 (PGE2) concentrations were established using plasma samples 
taken on d 0, d 3, d 10, d 17 and d 24 of each period.  Mean PGE2 values; separated by 
treatment and by day, are shown in Appendix 6. 
For mean PGE2 concentrations, there were no significant difference among 
treatments (P = 0.467). Though there is a numeric difference between diets at day 17 
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(Figure 4), there was no significant day effect (P = 0.816) on mean PGE2 concentrations 
in exercising yearlings. 
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Figure 4. Mean PGE2 concentration by diet 
 
  
PGE2 data were normalized to d 0 measurements of each period.   There were no 
significant day effect (P = 0.661) or treatment influence (P = 0.421) on normalized PGE2 
production among yearlings (Figure 5). It appeared that all normalized PGE2 values, 
regardless of treatment, decreased from d 0 to d 3. PGE2 production numerically 
increased in horses fed either CO or SBO diets between d 10 and d 17, though it was not 
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significantly different (P > 0.05). Horses consuming MCO diets had declining PGE2 
concentrations by d 17; however, there were no statistical variation between treatments  
(P > 0.05).  
 
-700
-600
-500
-400
-300
-200
-100
0
0 3 10 17 24
Day
PG
E2
 c
on
ce
nt
ra
tio
n 
(p
g/
m
l)
Corn Oil Menhaden/Corn Oil Soybean Oil
 
Figure 5. Normalized mean PGE2 concentration over a 24 day period 
 
As similar to Osteocalcin data, there were significant period effects in mean 
plasma PGE2 concentration (P<0.05) and in normalized PGE2 (P<0.05) (Table 13). There 
were numerical decreases in PGE2 concentrations from baseline values through the end of 
the trial (Figure 6). It appears that there was an adaptation to the exercise either 
physiologically or metabolically in the yearlings.  
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Table 13. PGE2 concentration (all groups)      
Period     1 2   3   Mean 
Mean PGE2  (ng/ml)                                             1150.29a 890.11a,b  770.98b  931.26 
   SEM       119.88      72.56        51.93  50.12 
           
Normalized PGE2 (ng/ml)                                    -248.56c -482.79c,d  -636.96d  -460.94 
  SEM         99.01        96.33      118.18   61.92 
                     a,bRow means not sharing superscripts differ (P = 0.012) 
                     c,dRow means not sharing superscripts differ (P = 0.046) 
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Figure 6. Mean PGE2 for all groups throughout the trial 
 
 
Fibrinogen    
Plasma samples collected on days 0, 3, 7, 10, 14, 17, 21, 24 and 28 of each period 
were analyzed for fibrinogen concentration.  Mean fibrinogen is shown in Appendix 7.  A 
significant treatment effect on mean fibrinogen concentration was not observed  
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(P = 0.886) Mean fibrinogen separated by treatments and by day of period are illustrated 
in Figure 7. 
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Figure 7. Mean fibrinogen concentration by diet over a 28 day period 
 
  
There was a significant period effect with mean fibrinogen (P < 0.001) (Table 14).  
Overall mean fibrinogen values were highest during period 1 and subsequently decreased 
throughout period 2 with lowest mean concentrations occurring within period 3  
(Figure 8). This pattern is similar to the PGE2 measurements previously mentioned. 
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Table 14. Mean fibrinogen concentrations among all groups         
Period       1   2   3
 (mg/dl)    460.79a  415.04b  401.16c
 SEM               5.80   2.75   1.63
a,b,c Row means not sharing superscripts differ (P < 0.001) 
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Figure 8. Mean fibrinogen concentrations for all groups throughout trial 
 
 
Despite the randomization of yearlings into treatment groups, there appeared to be 
a pattern in the group order of mean fibrinogen values (Figures 9-11).  Overall Group B 
were numerically higher during periods 1 and 2 than Group C, while Group C was 
numerically higher than Group A during the same periods. A numerical change in the 
observed group order appears during period 3 (Figure 11). Due to the apparent pattern, 
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data were normalized for each horse back to d 0 of each period to evaluate change in 
fibrinogen concentrations over 28 days.  
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Figure 9. Mean fibrinogen concentrations by group: Period 1 
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Figure 10. Mean fibrinogen concentrations by group: Period 2 
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 Figure 11. Mean fibrinogen concentrations by group: Period 3 
 
Mean normalized data for fibrinogen concentrations is shown in Appendix 8 and 
illustrated in Figure 12. When normalized data were analyzed, there was a significant 
effect of diet on fibrinogen concentrations (P < 0.001). Average normalized fibrinogen 
measurements among treatments are summarized in Table 15.  
 
 
Table 15. Normalized fibrinogen concentrations by treatment     
Treatment                   CO        MCO    SBO  
Mean Fibrinogen concentration (mg/dl)          -16.03a 4.31b  -37.73c  
             SEM             4.37        5.49      4.91  
            a,b,c Row means not sharing superscripts differ (P < 0.001) 
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 Mean normalized fibrinogen concentrations were lowest in horses fed SBO diet (P < 
0.007) and highest for horses fed MCO diet (P < 0.014).  Horses consuming CO diet expressed 
fibrinogen concentrations intermediate to measurements recorded from horses fed either SBO or 
MCO diets (P < 0.014).  
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Figure 12     Normalized fibrinogen concentrations by diet over a 28 day period. 
a,b,c Diets lacking common superscripts differ (P < 0.001) 
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CHAPTER V 
 
GENERAL DISCUSSION 
 
 
Experimental Design 
  
 The experimental model designated for the present study was a triplicated 3 X 3 
Latin Square designed to evaluate the effect of dietary PUFAs on bone biochemical 
markers and inflammatory response in exercising yearlings. This model is ideal when 
there are a limited number of animals to use. A switchback design creates a larger 
number of observations with higher degrees of freedom, resulting in a stronger statistical 
output if every period can be replicated in an identical manner. However, when the Latin 
Square was applied in this study, there was a significant effect of period. It is difficult to 
interpret if the dietary effects on the variables tested are a result of the actual diet or if it 
is confounded by the effect of period.   
A recent study investigating PUFA supplementation on inflammation in 
exercising horses used the same experimental model and had no period effects (Wilson et 
al, 2003). In the previous study, horses had been engaged in extensive training programs 
at their respective facilities, and upon arriving at the research center, underwent a 21-d 
pre-trial conditioning period to achieve an equal physical state among all horses.  The 
exercise protocol remained the same throughout the trial with no increase in intensities. A 
standardized exercise test (SET) was conducted on d 29, subjecting all horses to an 
exhaustive level of exercise, with inflammation markers measured prior to the SET and 
for 7 days after. The use of a SET established a more controlled observation of the 
variables in question and confirmed results previously published that indicate fibrinogen 
concentrations immediately drop after acute phase response to inflammation and then 
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subsequently increase in the days following (Allen and Kold,1988). The use of a SET in 
the present study would have been beneficial in properly evaluating diet effect on 
inflammation markers.   Exercise protocol for the present study was constant throughout 
as well, however it is likely the 14 d background period was not sufficient in establishing 
an equal conditioned state among the yearling horses.  In Wilson’s study (2003), horses 
were older; 3 and 4 yr of age, while the horses in the present study averaged 14 mo of age 
at the beginning of the trial.  It is possible that there are age differences in sub-clinical 
inflammation thresholds among horses. 
Fatty Acid Profiles 
 The dietary consumption of various oil sources incorporated at 8% of the diet, 
resulted in changes in plasma concentration (% by weight) of identifiable fatty acids from 
basal measurements in the horse. Percent change in fatty acid concentration of C14:0 
(mystric acid), C16:0 (palmitic acid), C18:0 (steric acid), C18:1 (oleic acid), C18:2 
(linoleic acid) and C18:3 (alpha linoleic acid) on d 28 did not differ among diets. These 
results are consistent with other studies evaluating fatty acid profiles in horses fed various 
oil sources (Wilson et al., 2003). Horses fed SBO diets had a greater percent decrease in 
C16:1 (palmoleic acid) concentration when compared to CO fed horses, however the 
decrease was similar to C16:1 concentration decreases found in horses fed MCO.   
Arachidonic acid concentrations were significantly higher at d 28 in horses 
consuming MCO compared to horses fed the CO. These results are similar with findings 
of Hall and associates (2004), where horses fed a menhaden oil diet for 12 weeks had 
higher concentrations of AA than horses supplemented with corn oil over the same 
timeframe; concluding that the higher amounts of AA found in the MCO diet are a result 
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of the exogenous amount of AA in the menhaden oil.  Despite an increase in Linoleic 
Acid; a precursor for Arachidonic Acid, there was a decrease in Arachidonic Acid 
concentrations (% by weight) in horses fed the CO diet for 28 days, indicating that 
perhaps an inhibition of LA elongating to AA is occurring. However, it should be 
stressed that fatty acid profiles in this study are expressed in percentage by weight units 
meaning that as one fatty acid changes in percentage by weight; it results in the percent 
change of another fatty acid. The interpretation of the fatty acids in this manner is a result 
of how the plasma samples were assayed. 
 In horses consuming a menhaden/corn oil supplemented-diet, C20:5 
(Eicosapentenoic Acid)  and C22:6 (Docosahexenoic Acid) increased 3 fold and nearly 7 
fold over baseline values, respectively. Percent changes in both EPA and DHA profiles in 
MCO fed horses were significantly higher compared to SBO fed horses. Changes in DHA 
profiles were different between MCO horses and CO horses with MCO horses having 
significantly higher increases at d 28.  Though numerically different, there was no 
statistical difference in percent change of EPA among MCO and CO fed horses.  In corn 
oil fed horses, there was an observed increase in C18:3 (alpha linolenic acid), the parent 
fatty acid to EPA. Therefore it is within reason to assume that the increase of EPA in 
these horses is a result of the increase in C18:3.   The incorporation of C20:5 and C22:6 
in the equine blood observed in the present study is consistent with previous research 
utilizing menhaden oil, or fish-derived EPA and DHA supplements as an omega 3 source 
in the diet of the mature horse (O’Conner et al., 2001, King et al., 2005)  and in the 
yearling horse (Vineyard et al., 2006).   
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Supplementation with mechanically extracted soybean oil resulted in decreases in 
all identified fatty acids with the exception of C 18:0 (steric acid), C18:2 (linoleic acid) 
and C22:6 (docosahexenoic acid).  Numerically, C18:2 profiles in SBO fed horses were 
of the highest profiles and percent change from baseline measurements; however, there 
were no significant differences in linoleic acid profiles between the diets.  
Fatty acid results reported here are consistent with other literature indicating 
blood fatty acid profiles are directly associated with the dietary intake of those fatty acids 
( Bjerve et al., 1993). 
Bone Biochemical Markers 
 There was no effect of diet or day on Osteocalcin concentration or ICTP 
concentrations in horses fed various ratios of omega 6: omega 3 PUFAs. These results are 
consistent with a previous study where Osteocalcin concentrations were unaltered in 
young growing rats fed an elevated omega-3 diet (Kelly et al., 2003).  The observed 
pattern in normalized mean OC concentrations was similar to a previous study evaluating 
Osteocalcin levels in yearlings undergoing various forms of exercise (Fenton et al., 
1999).  
 Due to the observed period effect on Osteocalcin measurements in the present 
study, data can not confirm or deny that consistency of these results. The experimental 
design used in this study is not appropriate for evaluating PUFA influence on bone 
activity in rapidly, growing yearlings, as the timeframe of 28 d appears to be insufficient 
in identifying significant changes to sensitive bone markers. Results suggest that the 
exercise protocol used was insufficient in stimulating a bone degradation response in 
ICTP or a bone turnover response for Osteocalcin.  
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This was the first study to investigate polyunsaturated fatty acid effects on bone 
activity in the horse. Future research is needed to further identify omega 6 and omega 3 
responsibilities in equine skeletal health.  
Inflammation Markers 
 There was no significant difference in PGE2 measurements as a result of diet. 
There was a significant period effect, with adaptation to exercise most likely being the 
contributing factor.  PGE2 concentrations among all horses were extremely variable, with 
high standard deviations resulting.  The assay used in this study had been previously 
validated using equine synovial fluid with little variation among measurements 
(Munsterman et al., 2005).  The variability among horses may be explained by plasma 
sample processing methods. Previous literature has indicated the addition of a 
prostaglandin inhibitor to samples prior to storage ( Bertone et al., 2001). The decision to 
use PGE2 as an inflammation marker was determined after the samples had been 
processed and stored; therefore an inhibitor was not added.  However, PGE2 
concentrations defined in this study were within the kit standards range, therefore the 
measurements are reliable data points. There is extensive information available on PGE2 
concentrations in equine synovial fluid, exudates and cultured medias, however there is 
little to no information regarding PGE2 levels in resting or exercising horses. One study 
reported mean plasma concentrations of PGE2 in normal horses to be 187.18 pg/ml 
(Owens et al.,1995). These measurements are significantly lower than concentrations 
observed in the present study, however, horses in Owens et al., study were measured at 
rest and then directly after light hand exercise.  PGE2 concentrations do not instantly 
increase after a stimulus; therefore samples taken that soon after cessation of exercise are 
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not reliable indicator of an inflammatory response. Past research indicated exudates PGE2 
increased 2 hrs after an inflammatory induction with levels peaking at 12 hrs (Higgins 
and Lee, 1984a) and remaining elevated up to 72 hrs (Guthrie et al., 1996).  Sample 
collection in this study was taken approximately 18 hrs post exercise; therefore 
concentrations may be of a recovery dilution rather than of peak levels.  This is one of the 
first studies to investigate PGE2 in horse plasma under exercising conditions. Further 
investigations are necessary to identify measurements of PGE2 over a 24 hr period in both 
resting and exercising horses to provide a template of normal plasma levels as well as 
establish if diurnal variation exists in plasma PGE2, as it does in other blood-borne 
biological markers. 
 Fibrinogen was the second marker used to evaluate inflammation. There was a 
significant difference in normalized fibrinogen. However, there was a significant period 
effect with this set of data, complicating the reliability of the results.  Horses fed SBO 
had a significantly lower normalized mean concentration of fibrinogen when compared to 
horses consuming either CO or MCO diets.   These results are consistent with previous 
research where horses consuming mechanically extracted soybean oil had lower 
fibrinogen concentrations compared to horse fed corn oil (Wilson et al., 2003). When 
horses in the present study consumed CO, the mean fibrinogen concentration was 
significantly lower (P<0.001) than horse fed MCO diet.  These results are inconsistent 
with findings in other mammals fed menhaden oil as a mediator of inflammation (Calder 
2002).  Menhaden oil in this study however was mixed with corn oil, possibility resulting 
in a competitive inhibition between omega 6 derivatives and omega 3 derivatives, 
allowing fibrinogen levels to remain elevated.  
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  Other research using equine models to measure inflammation marker production 
concluded that elevated n3 diets resulted in the decreased production of PGE2 levels in 
brochoalevolar lavage fluid cells (Hall et al., 2004) and in synovial membrane explant 
cultures (Munsterman et al., 2005). It is possible that the level of EPA and DHA supplied 
in the diet was not sufficient to alter biological responses. However, Caughey et al., 
(1996), reported that EPA concentration of approximately 1% of total mononuclear cell 
membrane fatty acid decreased cytokine production and that any increase in % EPA did 
not result in additional decrease of cytokines. The same study concluded that when 1.6g 
of EPA was supplemented, 1.6% of EPA was incorporated into the mononuclear cell 
membrane. Though plasma concentrations of fatty acids can not be compared to cell 
membrane concentrations, the mean percent by weight of EPA and DHA in the horses 
involved in this study was 1.36 % and 1.64% respectively. The evaluation of 
inflammation markers and their assuage as a result of the diet is a relatively new topic in 
equine research and needs further investigation. 
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CHAPTER VI 
SUMMARY AND CONCLUSIONS 
 
In recent years, there has been an increased interest in dietary fat, and its 
formulation in the diet has been reevaluated.  The dramatic change in food formulations 
has led to a greater dietary intake of plant oils such as corn, safflower, and soybean oil. 
These oils are high in linoleic acid, and have resulted in an elevated ratio of ω-6: ω-3 
fatty acids in human diets during the 20th century (Watkins et al., 2001b). However, 
recent studies have indicated that a high consumption of ω-6 PUFAs in conjunction with 
a low consumption of ω-3 PUFAs may contribute to the development of some chronic 
diseases, cancer, cardiovascular disease and skeletal disease (Watkins et al., 2003). Based 
on these discoveries, nutritional research has turned a large focus in the direction of ω-3 
PUFAs and their role in the diet. Evaluation of the omega 6 and omega 3 fatty acids 
within the equine diet is a relatively new subject, with little data to confirm if the benefits 
seen in other species can be duplicated in the horse.  
 Nine quarter horse yearlings were blocked by age and gender and randomly 
assigned one of three diets within a Latin Square experimental model.  Diets were 
supplemented with a variety of oil to achieve different levels of omega 6: omega 3 
polyunsaturated fatty acid ratios. Corn oil supplementation (CO) resulted in a 21.05:1 
omega 6: omega 3 PUFA ratio; Menhaden/Corn oil mix (MCO) resulted in a 12.7:1 ratio 
and the mechanically extruded Soybean Oil diet (SBO) had a calculated omega 6: omega 
3 ratio of 15.6:1.  
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 After a 14 day exercise pre-conditioning period, horses were placed in a 28 day 
diet and experimental exercise adaptation period. Blood samples were harvested bi-
weekly over the course of each period for evaluation of bone activity and inflammation 
response to diet, as well as to determine plasma fatty acid profiles in horses fed varying 
ratios of omega 6: omega 3 PUFAs.   
The bone formation marker, Osteocalcin, was not different among the diets, nor 
was the bone degradation marker ICTP.  The inflammation markers PGE2 and fibrinogen 
did not change as a result of diet. Fibrinogen data normalized from day 0 of each period 
indicate a significant difference between diets; with SBO fed horses exhibiting the lowest 
concentrations of fibrinogen when compared to CO fed horses and MCO fed horses     
(P< 0.001).  Data from the bone markers suggests that exercise was not intense enough to 
induce bone degradation or formation in the yearlings. Inflammation markers were 
recorded at measurements consistent with previous research to be sub-clinical levels of 
inflammation; however, these values were only seen in the first period with marked 
decreases in mean concentrations occurring in the preceding periods regardless of diet.  A 
strong period effect was evident with data collected from both inflammation markers as 
well as for the bone turnover marker Osteocalcin.  An adaptation to the exercise protocol 
and an unforeseen horse effect are likely the contributing factors to the perceived effect. 
The increased incorporation of the long chain fatty acids into equine plasma, 
arachidonic acid, eicosapenteonic acid and docosahexonic acid in horses fed the MCO 
diet compared to the other diets is consistent with previous research.  Concentrations of 
C18:2 (Linoleic Acid), the parent metabolite to arachidonic acid, were not significantly 
different between diets. Despite the menhaden oil being mixed with corn oil, there 
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appears to be sufficient amounts of EPA and DHA being measured in the plasma; mean 
increases were 4 fold and 6 fold above baseline values, respectively. This is one of the 
first studies investigating the short term (28 d) incorporation of EPA and DHA in horses. 
There was no significant carry over effect of these essential fatty acids found in equine 
plasma which is consistent with previous findings where concentrations of EPA and 
DHA were returning to basal levels as soon as d 9 after cessation of omega 3 
supplementation (King et al., 2005).   
The data presented indicated the experimental model used was insufficient in 
properly evaluating the multiple variables under question.  The use of a switchback 
model prevented an accurate assessment of dietary treatment on biochemical bone 
markers in rapidly growing yearlings.  The physiological change occurring in bone of this 
age group makes it difficult to measure a precise change as a result of the diet with this 
type of experimental design. A substitute method could be a straight blocking of the 
young horses by gender and age, randomly assigning each group one of the three diets, 
and having no changing of treatments.   
Incorporating a standard exercise test at the end of each period in the present 
model would have provided a consistent measurement among horses regarding treatment 
influence to the inflammatory response. Subjecting the horses to an exhaustive workout, 
then measuring inflammatory reaction and recovery over a certain period of time, would  
offer a more confident evaluation of sub-clinical inflammatory response to treatment in 
exercising yearlings.  A standard exercise test for the evaluation of acute phase protein 
concentrations has been successfully used in previous studies (Wilson et al., 2003, 
Wagner et al., 2006, Texas A&M University; unpublished results). 
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Due to an apparent period effect, the hypothesis of altering omega 6: omega 3 
ratios in the equine diet may influence inflammatory response and bone activity in the 
young exercising horse, can not be confidently confirmed nor denied.  Despite the 
apparent effect of period on the regarded variables, the patterns seen within the collected 
data quantify a need for further investigations in this area of equine nutrition. Future 
queries would benefit from the evaluation of PUFA regulation of eicosanoids in bone 
metabolism in the young horse as well as the mediating properties elevated omega 3 diets 
have in the inflammatory response. It would be useful to determine if dietary PUFA do in 
fact influence calcium absorption in horses, as seen in other species.  Previous research 
investigating fat-supplemented diets in equines determined that dietary fat had no bearing 
on the regulation of calcium (Bowman, 1977).   
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APPENDICES 
 
APPENDIX 1. MEAN FATTY ACID COMPOSITION (% BY WEIGHT) ALL HORSES, DAY 0 
 
 
 
APPENDIX 2. MEAN ICTP CONCENTRATION (ng/ml) BY DIET  AND DAY 
Day       0   14   28 
Mean ITCP Concentration 
(ng/ml) CO 27.41  21.04  24.08 
   SEM 4.25  1.34  3.54 
         
   MCO 22.43  20.41  21.16 
   SEM 2.53  1.31  2.08 
         
   SBO 25.33  23.53  20.26 
   SEM 6.00  2.72  1.53 
         
   All Groups 25.06  21.66  21.83 
      SEM 2.36   1.09   1.44 
 
Fatty Acid  All Groups 
                Mean                SEM 
C14:0  0.11 0.02 
      
C16:0  9.92 0.61 
      
C16:1(n-7)  0.29 0.01 
      
C18:0 17.86 0.35 
      
C18:1(n9) 10.31 0.44 
      
C18:2(n6) 52.91 0.45 
      
C18:3(n3) 1.21 0.36 
      
C20:4(n6) 1.93 0.06 
      
C20:5(n3) 0.02 0.01 
      
C22:6(n3) 0.10 0.03 
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APPENDIX 3. NORMALIZED MEAN ITCP CONCENTRATION (ng/ml) BY DIET AND DAY 
Day       0   14   28 
ITCP Concentration (ng/ml) CO 0.00  -1.96  1.08 
   SEM 0.00  1.47  2.48 
         
   MCO 0.00  -4.57  -3.81 
   SEM 0.00  2.73  3.74 
         
   SBO 0.00  0.01  -3.27 
   SEM 0.00  1.07  1.61 
         
   All Groups 0.00  -2.18  -2.00 
      SEM 0.00   1.11   1.59 
 
 
APPENDIX 4. MEAN OSTEOCALCIN CONCENTRATION BY DIET AND DAY 
Day         0   14   28 
Osteocalcin concentration (ng/ml)   CO 66.65  55.41  61.79 
    SEM 8.91  5.45  5.40 
          
    MCO 53.03  56.96  62.26 
    SEM 5.47  5.05  7.02 
          
    SBO 55.56  57.52  64.42 
    SEM 4.77  5.45  6.07 
          
    
All 
Groups 58.41  56.63  62.82 
        SEM 3.92   2.96   3.45 
 
 
APPENDIX 5. NORMALIZED MEAN OSTEOCALCIN CONCENTRATIONS (ng/ml) BY DIET AND DAY 
 
 
 
Day         0   14   28 
Osteocalcin 
concentration (ng/ml)   CO 0  -9.22  -2.84 
    SEM 0  6.07  4.63 
          
    MCO 0  -2.13  3.16 
    SEM 0  4.40  6.28 
          
    SBO 0  -7.89  -0.99 
    SEM 0  4.11  5.38 
          
    All Groups 0  -6.41  -0.22 
        SEM 0   2.81   3.07 
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    APPENDIX 6. MEAN FIBRINOGEN CONCENTRATIONS  BY DIET AND DAY 
 
 
 CO   MCO   SBO   
All 
Groups 
Day               
 (mg/dl)          0   438.203  426.118  459.251  441.191 
                      
SEM 17.4263  17.2495  22.932  11.0819 
        
3 419.183  429.716  440.431  429.777 
 23.8941  16.4935  21.5694  11.7077 
        
7 421.543  411.606  421.96  418.63 
 21.6949  12.6699  24.6601  11.5847 
        
10 421.543  423.201  431.61  438.915 
 19.6633  14.224  21.4637  11.0445 
        
14 452.6  402.61  400.32  420.498 
 18.25  24.3005  18.409  12.4417 
        
17 420.286  445.935  409.948  425.964 
 20.9233  15.1282  20.7775  11.1126 
        
21 427.019  426.919  413.45  422.641 
 19.2097  13.8866  28.8568  11.7029 
        
24 409.963  441.246  408.408  419.414 
 11.8131  14.5722  20.5041  9.62587 
        
28 401.663  420.68  406.61  409.958 
 16.7923  9.91258  21.2436  9.36807 
        
Mean (mg/dl) 427.499  426.077  422.927   
 SEM 6.48635   4.91481   7.56442     
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            APPENDIX 7. NORMALIZED MEAN FIBRINOGEN CONCENTRATIONS BY DIET AND DAY 
  
                    
CO        MCO         SBO      All Groups 
Day               
(mg/dl)                    0 
                    
0  0  0  0 
SEM 
                   
0  0  0  0 
        
3 -19.68  3.59  -18.82  -11.63 
 14.73  9.91  12.18  7.57 
        
7 -16.66  -3.14  -37.29  -19.64 
 13.8  18.35  15.93  9.27 
        
10 16.45  -2.83  -27.64  -5.59 
 10.57  14.11  11.84  7.73 
        
14 -5.84  -12.94  -91.52  -39.74 
 10.22  17.2  10.85  12.26 
        
17 -17.04  37.97  -16.59  1.42 
 9.95  10.94  18.57  9.33 
        
21 -19.37  0.93  -52.77  -23.91 
 14.03  18.89  13.89  9.91 
        
24 -36.43  16.06  -50.84  -24.82 
 13.25  24.24  7.24  10.58 
        
28 -44.73  0.47  -52.64  -31.82 
 15.03  21.36  15.54  10.92 
        
Mean (mg/dl) -16.03  4.31  -37.73   
 SEM 4.38  5.49   4.91     
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         APPENDIX 8. TOTAL DIET N6:N3 POLYUNSATURATED FATTY ACID RATIOS 
 
n6:n3 Ratios C14:0 C16:0 C16:1 C18:0 C18:1 C18:2 C18:3 C20:4 C20:5 C22:6 
            
CO diet grain 0.0676 8.1692 0.0832 1.4404 16.9988 20.358 0.9308 0.1092 0.1404 0.0364 
 hay 0.408 9.276 0.052 1.372 1.876 5.924 8.152 0.808 0.156 0.332 
 oil 0.0408 0.948 0.0352 0.1792 2.1424 4.468 0.0784 0 0 0 
Total  0.5164 18.3932 0.1704 2.9916 21.0172 30.75 9.1612 0.9172 0.2964 0.3684 
n6:n3 ratio 3.22           
            
MCO diet grain 0.0676 8.1692 0.0832 1.4404 16.9988 20.358 0.9308 0.1092 0.1404 0.0364 
 hay 0.408 9.276 0.052 1.372 1.876 5.924 8.152 0.808 0.156 0.332 
 oil 0.1456 1.028 0.1992 0.1944 1.8152 3.4416 0.0936 0.0128 0.2472 0.2704 
Total  0.6212 18.4732 0.3344 3.0068 20.69 29.7236 9.1764 0.93 0.5436 0.6388 
n6:n3 ratio 2.95           
            
SBO diet grain 0.0676 8.1692 0.0832 1.4404 16.9988 20.358 0.9308 0.1092 0.1404 0.0364 
 hay 0.408 9.276 0.052 1.372 1.876 5.924 8.152 0.808 0.156 0.332 
 oil 0.0056 0.8496 0.0056 0.3336 1.6624 4.4072 0.6464 0 0 0 
Total  0.4812 18.2948 0.1408 3.146 20.5372 30.6892 9.7292 0.9172 0.2964 0.3684 
n6:n3 ratio 3.04           
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APPENDIX 10. MEAN PGE2 CONCENTRATIONS (pg/ml) BY DIET AND DAY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 9.  DAY 0 PLASMA FATTY ACID COMPOSITON 
                          (% BY WEIGHT)       
                          
Horse   Diet C14:0 C16:0 C16:1 C18:0 C18:1 C18:2 C18:3 C20:4 C20:5 C22:6 
1A   0.06955 12.3215 0.29655 17.94015 8.97495 53.25195 2.61375 2.00025 0 0 
2A   0.0721 9.5319 0.2638 17.6457 9.672 54.1374 1.8966 1.8938 0 0.0709 
3A   0.12955 5.9978 0.36715 15.67305 11.6734 53.4635 2.72075 1.6973 0 0 
1B   0.0552 8.9186 0.2287 17.6281 10.9786 54.9316 0.2801 2.0117 0 0 
2B   0.0808 10.4323 0.30955 18.2171 12.7907 51.6306 0.1481 2.1726 0 0.1102 
3B   0.1139 10.0947 0.2651 18.8069 9.5635 51.3021 0.2369 2.1829 0 0.1766 
1C   0.2175 9.4894 0.3358 19.5641 9.3915 52.5964 0.9105 1.6588 0.0857 0.1851 
2C   0.1617 11.7043 0.3415 17.6951 8.971 53.7895 1.9832 1.8582 0 0.2332 
3C     0.0967 10.8639 0.2777 17.5886 10.7863 51.1205 0.1569 1.9165 0.0728 0.1202 
        PGE2 (pg/ml)   
                      D0       D3     D10    D17    D24 
CO   1028.556 749.7105 842.5743 890.2074 863.4798 
SEM  192.6991 135.9845 184.7216 148.566 185.4606 
       
MCO  928.1476 915.2614 943.837 721.5244 983.6442 
SEM  160.1556 160.4418 251.7125 109.8118 186.8593 
       
SBO  1176.841 926.7619 875.4658 1121.421 1011.877 
SEM  319.327 236.1728 211.6033 253.7075 195.7115 
       
All Groups 1044.515 858.8832 884.4436 910.2173 947.9935 
SEM   131.5259 97.43019 119.1397 104.198 105.9273 
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APPENDIX 11. ICTP AND OSTEOCALCIN CONCENTRATIONS  
              
Horse Diet Day ICTP (ng/ml) Osteocalcin (ng/ml) 
1A CO 0 34.29  69.9353  
1A CO 14 27.52  74.7396  
1A CO 28 50  72.15  
1A MCO 0 50  72.15  
1A MCO 14 27.062  64.187  
1A MCO 28 23.288  74.0613  
1A SBO 0 23.288  74.0613  
1A SBO 14 21.317  64.76  
1A SBO 28 23.886  52.426  
2A CO 0 28.27  80.178  
2A CO 14 20.547  71.2465  
2A CO 28 23.152  77.161  
2A MCO 0 23.152  77.161  
2A MCO 14 18.703  79.069  
2A MCO 28 20.01  88.656  
2A SBO 0 20.01  88.656  
2A SBO 14 16.455  60.30375  
2A SBO 28 18.434  87.89  
3A CO 0 19.651  49.8305  
3A CO 14 20.537  52.827  
3A CO 28 16.922  57.6035  
3A MCO 0 16.922  57.6035  
3A MCO 14 15.76  60.684  
3A MCO 28 16.626  64.326  
3A SBO 0 16.626  64.326  
3A SBO 14 15.376  64.78975  
3A SBO 28 15.233  57.771  
1B MCO 0 24.785  51.8866  
1B MCO 14 19.082  64.045  
1B MCO 28 16.418  42.8946  
1B SBO 0 16.418  42.8946  
1B SBO 14 21.37  45.05433  
1B SBO 28 18.833  67.379  
1B CO 0 18.833  67.379  
1B CO 14 17.201  61.355  
1B CO 28 17.886  53.3  
2B MCO 0 17.37  44.17  
2B MCO 14 25.157  62.95575  
2B MCO 28 33.635  92.143  
2B SBO 0 33.635  92.143  
2B SBO 14 38.515  82.427  
2B SBO 28 29.864  82.441  
2B CO 0 29.864  82.441  
2B CO 14 22.306  72.4345  
2B CO 28 20.016  84.515  
3B MCO 0 25.125  63.024  
3B MCO 14 20.246  61.53175  
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APPENDIX 
 Horse 
11 (CONT) 
Diet Day ICTP(ng/ml)  Osteocalcin(ng/ml)  
3B MCO 28 25.811  59.91075  
3B SBO 0 25.811  59.91075  
3B SBO 14 27.043  63.3525  
3B SBO 28 19.127  55.732  
3B CO 0 19.127  55.732  
3B CO 14 22.68  45.779  
3B CO 28 21.367  45.538  
1C SBO 0 15.255  46.045  
1C SBO 14 16.086  31.254  
1C SBO 28 15.687  32.878  
1C CO 0 15.687  32.878  
1C CO 14 15.594  33.726  
1C CO 28 17.575  35.723  
1C MCO 0 17.575  35.723  
1C MCO 14 17.219  30.918  
1C MCO 28 12.771  33.071  
2C SBO 0 36.001  60.917  
2C SBO 14 34.016  68.3926  
2C SBO 28 22.804  57.3435  
2C CO 0 22.804  57.3435  
2C CO 14 25.88  56.0905  
2C CO 28 31.025  74.6135  
2C MCO 0 31.025  74.6135  
2C MCO 14 23.399  54.504  
2C MCO 28 23.577  66.7083  
3C SBO 0 24.748  59.725  
3C SBO 14 21.619  37.335  
3C SBO 28 18.49  85.9285  
3C SBO 0 18.49  85.9285  
3C CO 14 17.094  30.51  
3C CO 28 18.794  55.503  
3C MCO 0 18.794  55.503  
3C MCO 14 17.033  34.783  
3C MCO 28 18.278   38.531  
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APPENDIX 12.  FIBRINOGEN CONCENTRATION (mg/dl)     
Horse   Diet   Day Fibrinogen (mg/dl) 
1A  MCO  0 517.1  
1A  MCO  3 544.92  
1A  MCO  7                              -  
1A  MCO  10                              -  
1A  MCO  14                                 
1A  MCO  17                              -  
1A  MCO  21 473.25  
1A  MCO  24 440.87  
1A  MCO  28 434.97  
1A  SBO  0 434.97  
1A  SBO  3 418.07  
1A  SBO  7 392.79  
1A  SBO  10 382.87  
1A  SBO  14 366.36  
1A  SBO  17 478.43  
1A  SBO  21 390.55  
1A  SBO  24 398.25  
1A  SBO  28 464.12  
1A  CO  0 464.12  
1A  CO  3 506.25  
1A  CO  7 388.41  
1A  CO  10 481.99  
1A  CO  14                             -  
1A  CO  17 440.83  
1A  CO  21 408  
1A  CO  24 398.33  
1A  CO  28 428.99  
1A`  CO  28                             -  
1B  SBO  0 533.84  
1B  SBO  3 502.43  
1B  SBO  7 442.53  
1B  SBO  10 524.13  
1B  SBO  14 439.93  
1B  SBO  17                             -  
1B  SBO  21 572.62  
1B  SBO  24 505.29  
1B  SBO  28 423.63  
1B  CO  0 423.63  
1B  CO  3 432.77  
1B  CO  7 461.31  
1B  CO  10 435.5  
1B  CO  14 463.44  
1B  CO  17 427.87  
1B  CO  21 442.68  
1B  CO  24 373.91  
1B  CO  28 430.91  
1B  MCO  0 430.91  
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APPENDIX 
Horse 
12 (Continued) 
 Diet  Day Fibrinogen(mg/dl) 
 
 
1B  MCO  3 395.88  
1B  MCO  7 401.86  
1B  MCO  10 417.24  
1B  MCO  17 450.1  
1B  MCO  21 373.2  
1B  MCO  24 426.25  
1B  MCO  28 408.49  
1C  CO  0 526.63  
1C  CO  3 494.36  
1C  CO  7 473.48  
1C  CO  10 513.51  
1C  CO  14 519.33  
1C  CO  17 464.81  
1C  CO  21 442.61  
1C  CO  24 446.73  
1C  CO  28 454.14  
1C  MCO  0 454.14  
1C  MCO  3 468.9  
1C  MCO  7 435.54  
1C  MCO  10 460.71  
1C  MCO  14                             -  
1C  MCO  17 484.43  
1C  MCO  21 442.61  
1C  MCO  24 446.73  
1C  MCO  28 454.14  
1C  SBO  0 507.39  
1C  SBO  3 408.84  
1C  SBO  7 376.55  
1C  SBO  10 424.9  
1C  SBO  14 377.05  
1C  SBO  17 435.99  
1C  SBO  21 415.94  
1C  SBO  24 420.08  
1C  SBO  28 463.24  
2A  MCO  0 420.28  
2A  MCO  3 428.39  
2A  MCO  7 400.77  
2A  MCO  10 415.46  
2A  MCO  14 427.35  
2A  MCO  21 374.25  
2A  MCO  24 365.05  
2A  MCO  28 397.39  
2A  SBO  0 397.39  
2A  SBO  3 431.58  
2A  SBO  7 369.98  
2A  SBO  10 388.21  
2A  SBO  14 338.97  
2A  SBO  17 366.15  
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Horse 
12 (Continued) 
 Diet             Day   Fibrinogen (mg/dl)  
2A  SBO  21 323.65  
2A  SBO  24 342.58  
2A  SBO  28 356.38  
2A  CO  0 356.38  
2A  CO  3 351.35  
2A  CO  7 303.56  
2A  CO  10 382.08  
2A  CO  17 315.27  
2A  CO  21 325.61  
2A  CO  24 368.54  
2A  CO  28 336.55  
2B  SBO  0 547.61  
2B  SBO  3 538.83  
2B  SBO  7 544.63  
2B  SBO  10 513.61  
2B  SBO  14 436.56  
2B  SBO  21 480.56  
2B  SBO  24 472.76  
2B  SBO  28 482.71  
2B  CO  0 482.71  
2B  CO  3 495.81  
2B  CO  7 514.2  
2B  CO  10 556.91  
2B  CO  14 485.4  
2B  CO  17 477.77  
2B  CO  21 524.46  
2B  CO  24 425.61  
2B  CO  28 415.48  
2B  MCO  0 415.48  
2B  MCO  3 409.28  
2B  MCO  7 453.45  
2B  MCO  10 447.14  
2B  MCO  14                              -  
2B  MCO  17 460.73  
2B  MCO  21 418.12  
2B  MCO  24 462.55  
2B  MCO  28 436.85  
2C  CO  0 432.15  
2C  CO  3 432.58  
2C  CO  7 436.56  
2C  CO  10 465.37  
2C  CO  14 412.34  
2C  CO  17                             -  
2C  CO  21 422.31  
2C  CO  24 457.95  
2C  CO  28 444.91  
2C  MCO  0 444.91  
2C  MCO  3 416.96  
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Horse 
12 (Continued) 
 Diet  Day Fibrinogen (mg/dl)  
2C  MCO  7 349.35  
2C  MCO  10 373.26  
2C  MCO  14 380.61  
2C  MCO  17 460.81  
2C  MCO  21 398.75  
2C  MCO  28 398.09  
2C  SBO  0 398.09  
2C  SBO  3 444.72  
2C  SBO  7 372.06  
2C  SBO  10 392.86  
2C  SBO  14                             -  
2C  SBO  17 390.12  
2C  SBO  21 342.75  
2C  SBO  24 362.11  
2C  SBO  28 374.97  
3A  MCO  0 449.92  
3A  MCO  3 420.78  
3A  MCO  7 442.99  
3A  MCO  10 490.15  
3A  MCO  14 455.95  
3A  MCO  17                             -  
3A  MCO  21 492.59  
3A  MCO  24 487.87  
3A  MCO  28 389.31  
3A  SBO  0 389.31  
3A  SBO  3 364.02  
3A  SBO  7 401.32  
3A  SBO  10 427.75  
3A  SBO  14                              -  
3A  SBO  17                              -  
3A  SBO  21                              -  
3A  SBO  24 335.74  
3A  SBO  28 372.69  
3A  CO  0 372.69  
3A  CO  3 333.23  
3A  CO  7 353.91  
3A  CO  10                             -  
3A  CO  14                             -  
3A  CO  17 382.46  
3A  CO  21                             -  
3A  CO  24                             -  
3A  CO  28                             -  
3B  SBO  0 529.81  
3B  SBO  3 505.84  
3B  SBO  7 544.63  
3B  SBO  10 490.97  
3B  SBO  14 443.05  
3B  SBO  21 423.71  
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Horse 
12 (Continued) 
 Diet              Day  Fibrinogen (mg/dl)  
3B  SBO  24 466.88  
3B  SBO  28 435.17  
3B  CO  0 435.17  
3B  CO  3 322.1  
3B  CO  7 453.8  
3B  CO  10 412.55  
3B  CO  14 405.99  
3B  CO  17 432.99  
3B  CO  21 423.3  
3B  CO  24 385.6  
3B  CO  28 355.22  
3B  MCO  0 355.22  
3B  MCO  3 390.99  
3B  MCO  7 431.74  
3B  MCO  10 400.36  
3B  MCO  17 443.76  
3B  MCO  21 450.96  
3B  MCO  24 489.3  
3B  MCO  28 472.03  
3C  CO  0 450.35  
3C  CO  3 404.2  
3C  CO  7 408.66  
3C  CO  10 454.86  
3C  CO  14 429.1  
3C  CO  17                             -  
3C  CO  21 427.18  
3C  CO  24 423.03  
3C  CO  28 347.1  
3C  MCO  0 347.1  
3C  MCO  3 391.34  
3C  MCO  7 377.15  
3C  MCO  10 381.29  
3C  MCO  14 346.53  
3C  MCO  17 375.78  
3C  MCO  21 418.54  
3C  MCO  24 411.35  
3C  MCO  28 394.85  
3C  SBO  0 394.85  
3C  SBO  3 349.55  
3C  SBO  7 353.15  
3C  SBO  10 339.19  
3C  SBO  14                             -  
3C  SBO  17 379.05  
3C  SBO  21 357.82  
3C  SBO  24 371.98  
3C   SBO   28 286.58   
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APPENDIX 13.  MEAN PGE2 CONCENTRATION 
Horse   Diet Day PGE2 (pg/ml) 
1A  CO 0 820.1  
1A  CO 3 411.7785  
1A  CO 10 245.883  
1A  CO 17 665.5075  
1A  CO 24 2058.685  
1A  MCO 0 522.7371  
1A  MCO 3 545.9  
1A  MCO 10                             -  
1A  MCO 17 425.68  
1A  MCO 24 874.282  
1A  SBO 0 630.7964  
1A  SBO 3                            -  
1A  SBO 10 587.2  
1A  SBO 17 1145.9  
1A  SBO 24 1089.5  
1B  MCO 0 1211.58  
1B  MCO 3 870.154  
1B  MCO 10                           -  
1B  MCO 17                           -  
1B  MCO 24                           -  
1B  SBO 0 906.6753  
1B  SBO 3 497.25  
1B  SBO 10 576.8  
1B  SBO 17 516.15  
1B  SBO 24 401.03  
1B  CO 0 721.7807  
1B  CO 3 1041.045  
1B  CO 10 1072.67  
1B  CO 17 591.9884  
1B  CO 24 556.0778  
1C  SBO 0 3119.11  
1C  SBO 3 2021.483  
1C  SBO 10 2462.471  
1C  SBO 17 1644.165  
1C  SBO 24 1811.803  
1C  CO 0 1893.737  
1C  CO 3 1709.2  
1C  CO 10 1718.18  
1C  CO 17 1424.975  
1C  CO 24 1486.725  
1C  MCO 0 915.2247  
1C  MCO 3 1524.865  
1C  MCO 10 1764.549  
1C  MCO 17 1098.2  
1C  MCO 24 1414.5  
2A  CO 0 703.6  
2A  CO 3 652.75  
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Horse 
13 (Continued) 
 Diet Day PGE2 (pg/ml)  
2A  CO 10 477.65  
2A  CO 17 639.02  
2A  CO 24 643.53  
2A  MCO 0 676.8739  
2A  MCO 3 501.7  
2A  MCO 10 446.75  
2A  MCO 17 482.7  
2A  MCO 24 524.8  
2A  SBO 0 486.9198  
2A  SBO 3 400.6  
2A  SBO 10 900.025  
2A  SBO 17 542.923  
2A  SBO 24 522.105  
2B  MCO 0 600.355  
2B  MCO 3 1354.543  
2B  MCO 10 1088.59  
2B  MCO 17 1259.215  
2B  MCO 24 1028.934  
2B  SBO 0 842.3466  
2B  SBO 3 1048.76  
2B  SBO 10 549.53  
2B  SBO 17 818.7795  
2B  SBO 24 1263.415  
2B  CO 0 627.0946  
2B  CO 3 499.6  
2B  CO 10 896.504  
2B  CO 17 461.2  
2B  CO 24 570  
2C  SBO 0 2540.42  
2C  SBO 10 454.4  
2C  SBO 17 2639.45  
2C  SBO 24 965.2  
2C  CO 0 2100.586  
2C  CO 3 680.3  
2C  CO 10 1374.305  
2C  CO 17 1556.23  
2C  CO 24 672.5  
2C  MCO 0 1186.399  
2C  MCO 3 1021.2  
2C  MCO 10 573.9  
2C  MCO 17 692.6  
2C  MCO 24                            -  
3A  CO 0 463.148  
3A  CO 3 422.15  
3A  CO 10                           -  
3A  CO 17 390.7676  
3A  CO 24 398.75  
3A  MCO 0 446.9888  
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13 (Continued) 
 Diet            Day        PGE2 (pg/ml)  
3A  MCO 3 352.1  
3A  MCO 10 385.35  
3A  MCO 17 446.2  
3A  MCO 24 409.2  
3A  SBO 0 541.8162  
3A  SBO 3 428.8  
3A  SBO 10 557.575  
3A  SBO 24 380.5  
3B  MCO 0 1985.766  
3B  MCO 3 1591.57  
3B  MCO 10 1937.04  
3B  MCO 17 784.4  
3B  MCO 24 1818.994  
3B  SBO 0 721.983  
3B  SBO 3 1487.94  
3B  SBO 10 1166.691  
3B  SBO 17 1013.903  
3B  SBO 24 1661.463  
3B  CO 0 816.3435  
3B  CO 3 583.4707  
3B  CO 10 635.95  
3B  CO 17 1362.133  
3B  CO 24 447.95  
3C  SBO 0 801.5  
3C  SBO 3 602.5  
3C  SBO 10 624.5  
3C  SBO 17 650.1  
3C  SBO 24                           -  
3C  CO 0 1110.612  
3C  CO 3 747.1  
3C  CO 10 319.4525  
3C  CO 17 920.045  
3C  CO 24 937.1  
3C  MCO 0 807.404  
3C  MCO 3 475.322  
3C  MCO 10 410.6806  
3C  MCO 17 583.2  
3C   MCO 24 814.8  
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APPENDIX 14. ANOVA FOR MEAN FIBRINOGEN CONCENTRATION (mg/dl) 
Source   Df Partial SS MS F-value P-value 
Model   8 230396.8 28799.6 14.73 0.000 
Period   2 136551.9 68275.96 34.91 0.000 
Diet     2 469.65 234.83 0.12 0.886 
Diet x Period 4 93283.76 23320.94 11.92 0.000 
Residual   206 402894.4 1955.79   
Total   214 438150 2037.9     
       
APPENDIX 15. ANOVA FOR NORMALIZED MEAN FIBRINOGEN CONCENTRATION (mg/dl) 
Source   Df Partial SS MS F-value P-value   
Model   28 137289.3 4903.18 1.9 0.0066  
Period   2 4115.88 2057.94 0.8 1.4522  
Day   8 47079.16 5884.89 2.28 0.0238  
Diet     2 50942.22 25471.11 9.86 0.0001  
Diet x Day 16 32889.22 2055.57 0.8 0.689  
Residual   186 480299.5 2582.25    
Total   214 438150 2037.9        
 
APPENDIX 16. ANOVA FOR MEAN PGE2 CONCENTRATION (pg/ml) 
Source   Df Partial SS MS F-value P-value 
Model   16 4687082 292942.7 0.92 0.544 
Period   2 2898955 1449478 4.57 0.012 
Diet     2 485722.5 242861.2 0.77 0.467 
Day   4 492146.5 123036.6 0.39 0.816 
Diet x Day 8 652812.5 81601.56 0.26 0.977 
Residual   108 34243454 317069   
Total   124 38930536 313955.9     
       
APPENDIX  17.ANOVA FOR NORMALIZED MEAN PGE2 CONCENTRATION (pg/ml) 
Source   Df Partial SS MS F-value P-value 
Model   16 5730186 358136.6 0.97 0.499 
Period   2 2337642 1168821 3.15 0.046 
Diet     2 646834.5 323417.3 0.87 0.421 
Day   4 895342.5 223835.6 0.6 0.661 
Diet x Day 8 1873666 234208.3 0.63 0.749 
Residual   110 40801478 370922.5   
Total   124 46531664 369298.9     
 
APPENDIX 18. ANOVA FOR MEAN ICTP CONCENTRATION (ng/ml)  
Source   Df Partial SS MS F-value P-value 
Model   10 445.69 44.56 1 0.459 
Period   2 202.31 101.15 2.26 0.1147 
Diet     2 66.49 33.24 0.74 0.481 
Day   2 10.43 5.21 0.12 0.89 
Diet x Day 4 105.13 26.28 0.59 0.673 
Residual   52 2329.16 44.79   
Total   62 2774.86 44.75     
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APPENDIX 19. ANOVA FOR NORMALIZED MEAN ICTP CONCENTRATION (ng/ml) 
Source   Df Partial SS MS F-value P-value   
Model   8 205.86 25.73 0.5 0.848  
Diet     2 11.63 5.82 0.11 0.893  
Day   2 84.85 42.43 0.83 0.442  
Diet x Day 4 96.07 24.02 0.47 0.757  
Residual   54 2760.16 51.11    
Total   62 2966.03 47.84       
        
 APPENDIX 20. ANOVA FOR MEAN ICTP CONCENTRATION (ng/ml)  DAY 28 
Source   Df Partial SS MS F-value P-value  
Model   2 71.84 35.92 0.62 0.545  
Diet     2 71.84 35.92 0.62 0.545  
Residual   24 1383.17 57.63    
Total   26 1455.02 55.96      
 
APPENDIX 21. ANOVA FOR NORMALIZED MEAN ICTP CONCENTRATION (ng/ml)  DAY 28 
Source   Df Partial SS MS F-value P-value     
Model   2 71.84 35.92 0.59 0.562   
Diet     2 71.84 35.92 0.59 0.562   
Residual   24 1464.06 61     
Total   26 1535.91 59.07         
 
APPENDIX 22. ANOVA FOR MEAN OSTEOCALCIN CONCENTRATION (ng/ml)   
Source   Df Partial SS MS F-value P-value   
Model   8 1117.14 139.64 0.49 0.861   
Diet     2 232.32 116.16 0.41 0.668   
Day   2 690.76 345.38 1.21 0.305   
Diet x Day 4 158.74 39.69 0.14 0.967   
Residual   72 20578.59 285.81     
Total   80 21695.73 271.19       
         
APPENDIX  23.ANOVA FOR NORMALIZED MEAN OSTEOCALCIN CONCENTRATION (ng/ml) 
Source   Df Partial SS MS F-value P-value     
Model   10 2209.87 220.99 1.45 0.177   
Period   2 1069.09 534.55 3.51 0.035   
Diet     2 274.97 137.49 0.9 0.41   
Day   2 714.81 357.41 2.35 0.103   
Diet x Day 4 144.5 36.13 0.24 0.916   
Residual   70 10667.75 152.39     
Total   80 12877.62 160.97         
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APPENDIX 24. ANOVA FOR MEAN MYSTRIC ACID  DAY 28    
Source   Df Partial SS MS F-value P-value   
Model   8 0.116 0.014 2.54 0.047   
Period   2 0.016 0.008 1.46 0.259   
Diet     2 0.043 0.021 3.81 0.042   
Diet x Period 4 0.056 0.014 2.45 0.083   
Residual   18 0.103 0.005     
Total   26 0.219 0.008       
       
APPENDIX 25. ANOVA FOR MEAN PALMITIC ACID  DAY 28  
Source   Df Partial SS MS F-value P-value 
Model   8 62.59 7.82 2.83 0.032 
Period   2 39.99 19.99 7.23 0.005 
Diet     2 16.41 8.2 2.97 0.077 
Diet x Period 4 6.18 1.54 0.56 0.694 
Residual   18 49.76 2.76   
Total   26         
       
APPENDIX 26. ANOVA FOR MEAN PALMOLEIC ACID DAY 28  
Source   Df Partial SS MS F-value P-value 
Model   8 0.091 0.011 3.64 0.011 
Period   2 0.047 0.023 7.64 0.004 
Diet     2 0.028 0.014 4.55 0.025 
Diet x Period 4 0.014 0.003 1.18 0.351 
Residual   18 0.056 0.003   
Total   26 0.147 0.005     
 
APPENDIX 27. ANOVA FOR MEAN STERIC ACID  DAY 28   
Source   Df Partial SS MS F-value P-value 
Model   8 107.84 13.48 3.73 0.009 
Period   2 61.61 30.81 8.53 0.003 
Diet     2 29.44 14.72 4.08 0.035 
Diet x Period 4 16.79 4.198 1.16 0.36 
Residual   18 65.01 3.61   
Total   26 172.86 6.65     
       
APPENDIX 28.ANOVA FOR MEAN OLEIC ACID  DAY 28  
Source   Df Partial SS MS F-value P-value 
Model   8 23.23 2.9 1.45 0.242 
Period   2 0.95 0.47 0.24 0.791 
Diet     2 1.38 0.69 0.35 0.712 
Diet x Period 4 20.89 5.22 2.61 0.07 
Residual   18 35.99 1.99   
Total   26 59.23 2.28     
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APPENDIX 29.  ANOVA FOR MEAN LINOLEIC ACID  DAY 28  
Source   Df Partial SS MS F-value P-value 
Model   8 54.28 6.78 0.83 0.586 
Period   2 11.96 5.98 0.73 0.494 
Diet     2 28.83 14.41 1.77 0.198 
Diet x Period 4 13.49 3.37 0.41 0.796 
Residual   18 146.62 8.15   
Total   26 200.91 7.73     
       
APPENDIX 30. ANOVA FOR MEAN ALPHA LINOLENIC ACID  DAY 28 
Source   Df Partial SS MS F-value P-value 
Model   8 0.313 0.039 0.89 0.545 
Period   2 0.045 0.022 0.51 0.609 
Diet     2 0.117 0.058 1.33 0.289 
Diet x Period 4 0.151 0.037 0.86 0.509 
Residual   18 0.794 0.044   
Total   26 1.106 0.0426     
       
APPENDIX 31.  ANOVA FOR MEAN ARACHIDONIC ACID DAY 28 
Source   Df Partial SS MS F-value P-value 
Model   8 2.09 0.262 8.42 0.0001 
Period   2 0.08 0.04 1.29 0.301 
Diet     2 1.67 0.836 26.86 0 
Diet x Period 4 0.35 0.09 2.77 0.059 
Residual   18 0.56 0.03   
Total   26 2.65 0.1     
       
APPENDIX 32. ANOVA  FOR MEAN EICOSAPENTEONIC ACID  DAY 28 
Source   Df Partial SS MS F-value P-value 
Model   8 11.31 1.41 10.63 0 
Period   2 0.32 0.16 1.2 0.323 
Diet     2 10.38 5.19 39.01 0 
Diet x Period 4 0.61 0.15 1.15 0.365 
Residual   18 2.39 0.13   
Total   26 13.71 0.53     
       
APPENDIX 33.  ANOVA FOR MEAN DOCOSAHEXENONIC ACID  DAY 28 
Source   Df Partial SS MS F-value P-value 
Model   8 13.74 1.71 11.91 0 
Period   2 0.1 0.05 0.35 0.708 
Diet     2 13.55 6.77 46.96 0 
Diet x Period 4 0.09 0.02 0.16 0.956 
Residual   18 2.59 0.144   
Total   26 16.34 0.63     
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APPENDIX 34.  ANOVA FOR % Δ  MYSTRIC ACID    
Source   Df Partial SS MS F-value P-value 
Model   8 139621.9 17452.74 2.04 0.0995 
Period   2 22313.3 11156.65 1.3 0.2957 
Diet     2 52572.44 26286.22 3.07 0.071 
Diet x Period 4 64736.15 16184.04 1.89 0.1555 
Residual   18 153911.4 8550.63   
Total   26 293533.4 11289.74     
       
APPENDIX 35.  ANOVA FOR  % Δ PALMITIC ACID   
Source   Df Partial SS MS F-value P-value 
Model   8 7199.52 899.94 1.38 0.2687 
Period   2 3812.6 1906.3 2.93 0.0792 
Diet     2 2178.2 1089.1 1.67 0.2154 
Diet x Period 4 1208.72 302.17 0.46 0.761 
Residual   18 11712.11 650.67   
Total   26         
       
APPENDIX 36.  ANOVA FOR  % Δ PALMOLEIC ACID   
Source   Df Partial SS MS F-value P-value 
Model   8 13465.64 1683.21 4.46 0.004 
Period   2 6392.26 3196.13 8.48 0.0025 
Diet     2 3652.92 1826.45 4.84 0.0208 
Diet x Period 4 3420.46 855.12 2.27 0.102 
Residual   18 6787.98 377.11   
Total   26 20253.63 778.98     
       
APPENDIX  37.  ANOVA FOR % Δ  STERIC ACID   
Source   Df Partial SS MS F-value P-value 
Model   8 3284.95 410.62 2.28 0.0702 
Period   2 1840.75 920.38 5.1 0.0175 
Diet     2 914.07 457.04 2.53 0.1072 
Diet x Period 4 530.12 132.53 0.73 0.5801 
Residual   18 3246.03 180.33   
Total   26 6530.97 251.19     
 
APPENDIX 38. ANOVA FOR   % Δ  OLEIC ACID   
Source   Df Partial SS MS F-value P-value 
Model   8 3965.05 495.63 1.04 0.4462 
Period   2 128.81 64.41 0.13 0.8749 
Diet     2 314.12 157.06 0.33 0.7244 
Diet x Period 4 3522.12 880.53 1.84 0.1651 
Residual   18 8613.64 478.53   
Total   26 12578.68 483.79     
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APPENDIX 39.  ANOVA FOR  % Δ  LINOLEIC ACID   
Source   Df Partial SS MS F-value P-value 
Model   8 199.29 24.91 0.78 0.6294 
Period   2 43.49 21.74 0.68 0.5208 
Diet     2 102.88 51.44 1.6 0.2292 
Diet x Period 4 52.91 13.23 0.41 0.798 
Residual   18 578.49 32.13   
Total   26 777.79 29.92     
       
APPENDIX 40. ANOVA FOR  % Δ ALPHA LINOLENIC ACID  
Source   Df Partial SS MS F-value P-value 
Model   8 82949.68 10368.71 0.94 0.5071 
Period   2 7325.68 3662.85 0.33 0.7211 
Diet     2 9530.89 4765.45 0.43 0.6549 
Diet x Period 4 66093.09 16523.27 1.5 0.2433 
Residual   18 197960.9 10997.83   
Total   26 280910.6 10804.25     
       
APPENDIX 41. ANOVA FOR  % Δ  ARACHIDONIC ACID  
Source   Df Partial SS MS F-value P-value 
Model   8 7642.42 955.3 2.74 0.0361 
Period   2 76.18 38.09 0.11 0.8971 
Diet     2 5617.64 2808.82 8.06 0.0032 
Diet x Period 4 1948.59 487.15 1.4 0.2747 
Residual   18 6274.79 348.59   
Total   26 13917.22 535.27     
 
APPENDIX  42. ANOVA  FOR  % Δ  EICOSAPENTEONIC ACID  
Source   Df Partial SS MS F-value P-value 
Model   8 1579858 197482.3 2.44 0.0553 
Period   2 214199.7 107099.8 1.32 0.2909 
Diet     2 665505 332752.5 4.11 0.0338 
Diet x Period 4 700153.6 175038.4 2.16 0.1146 
Residual   18 1456536 80918.65   
Total   26 3036394 116784.4     
       
 
APPENDIX  43. ANOVA FOR  % Δ DOCOSAHEXENONIC ACID  
Source   Df Partial SS MS F-value P-value 
Model   8 3488345 436043.2 8.16 0.0001 
Period   2 186473.1 93236.56 1.75 0.2028 
Diet     2 2832606 1416303 26.51 0.0000 
Diet x Period 4 469266.7 117316.7 2.2 0.1105 
Residual   18 961476.5 53415.35   
Total   26 4449822 171146.9     
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APPENDIX  44. ANOVA FOR MEAN MYSTRIC ACID  DAY 0  
Source   Df Partial SS MS F-value P-value 
Model   2 0.010381 0.005191 2.75 0.1424 
Group   2 0.010381 0.005191 2.75 0.1424 
Residual   6 0.011345 0.001891   
Total   8 0.021726 0.002716     
       
       
APPENDIX  45.  ANOVA FOR MEAN PALMITIC ACID  DAY 0  
Source   Df Partial SS MS F-value P-value 
Model   2 3.006495 1.503247 0.38 0.7004 
Group   2 3.006495 1.503247 0.38 0.7004 
Residual   6 23.85022 3.975038   
Total   8 26.85672 3.35709     
       
APPENDIX 46. ANOVA FOR MEAN PALMOLEIC ACID  DAY 0  
Source   Df Partial SS MS F-value P-value 
Model   2 0.004352 0.002176 1.15 0.3777 
Group   2 0.004352 0.002176 1.15 0.3777 
Residual   6 0.011351 0.001892   
Total   8 0.015703 0.001963     
 
APPENDIX 47. ANOVA FOR MEAN STERIC ACID  DAY 0   
Source   Df Partial SS MS F-value P-value 
Model   2 2.714702 1.357351 1.31 0.3366 
Group   2 2.714702 1.357351 1.31 0.3366 
Residual   6 6.203082 1.033847   
Total   8 8.917784 1.114472     
       
APPENDIX 48. ANOVA FOR MEAN OLEIC ACID  DAY 0  
Source   Df Partial SS MS F-value P-value 
Model   2 3.105915 1.552950 0.85 0.4732 
Group   2 3.105915 1.552950 0.85 0.4732 
Residual   6 10.963910 1.827310   
Total   8 14.069830 1.758720     
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APPENDIX 49. ANOVA FOR MEAN LINOLEIC ACID DAY 0  
Source   Df Partial SS MS F-value P-value 
Model   2 2.25091 1.125459 0.56 0.5985 
Group   2 2.25091 1.125459 0.56 0.5985 
Residual   6 12.062 2.010334   
Total   8 14.31292 1.789116     
       
APPENDIX 50. ANOVA FOR MEAN ALPHA LINOLENIC ACID  DAY 0 
Source   Df Partial SS MS F-value P-value 
Model   2 7.36439 3.68219 10.54 0.0109 
Group   2 7.36439 3.68219 10.54 0.0109 
Residual   6 2.09537 0.34922   
Total   8 9.45976       
APPENDIX 51. ANOVA FOR MEAN ARACHIDONIC ACID DAY 0  
Source   Df Partial SS MS F-value P-value 
Model   2 0.166517 0.083258 4.89 0.055 
Group   2 0.166517 0.083258 4.89 0.055 
Residual   6 0.102198 0.017033   
Total   8 0.268716 0.033549     
       
APPENDIX 52. ANOVA  FOR MEAN EICOSAPENTEONIC ACID DAY 0 
Source   Df Partial SS MS F-value P-value 
Model   2 0.00558 0.00279 3.92 0.0814 
Group   2 0.00558 0.00279 3.92 0.0814 
Residual   6 0.00427 0.00071   
Total   8 0.00985 0.00123     
       
APPENDIX 53.  ANOVA  FOR MEAN DOCOSAHEXENONIC ACID DAY 0 
Source   Df Partial SS MS F-value P-value 
Model   2 0.03651 0.01825 4.26 0.0705 
Group   2 0.03651 0.01825 4.26 0.0705 
Residual   6 0.02569 0.00428   
Total   8 0.06221 0.00777     
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